UNITED STATES

SECURITIES and EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2016~~2017

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-12537

QUALITY SYSTEMS, INC.

(Exact name of registrant as specified in its charter)



California (State or other jurisdiction of incorporation or organization) 18111 Von Karman Avenue, Suite 800, Irvine, California (Address of principal executive offices)	95-2888568 (IRS Employer Identification No.) 92612 (Zip Code)

(949) 255-2600 (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þNo o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þNo o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated ~~filer” and~~filer,” “smaller reporting ~~company”~~company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.



Large accelerated filer þ	Accelerated filer o
Non-accelerated filer o (Do not check if a smaller reporting company)	Small reporting company o
	Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes oNo þ

The number of outstanding shares of the Registrant’s common stock as of July ~~26, 2016~~28, 2017 was ~~61,506,483~~63,367,937 shares.

QUALITY SYSTEMS, INC.

TABLE OF CONTENTS

FORM 10-Q

FOR THE THREE MONTHS ENDED JUNE 30, ~~2016~~2017



	Item	Page

	PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements.
	Unaudited Consolidated Balance Sheets as of June 30, ~~2016~~2017 and March 31, ~~2016~~2017	3
	Unaudited Consolidated Statements of Comprehensive Income for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016	4
	Unaudited Consolidated Statements of Cash Flows for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016	5
	Notes to Unaudited Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2221
Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	3431
Item 4.	Controls and Procedures.	3431
	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings.	3532
Item 1A.	Risk Factors.	3634
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	3634
Item 3.	Defaults Upon Senior Securities.	3634
Item 4.	Mine Safety Disclosure.	3634
Item 5.	Other Information.	3634
Item 6.	Exhibits.	3735
	Signatures	3836

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

QUALITY SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)


	June 30, 2016			March 31, 2016			June 30, 2017			March 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	26,349		$	27,176		$	23,337		$	37,673
Restricted cash and cash equivalents	4,842			5,320			5,915			4,916
Marketable securities	—			9,297
Accounts receivable, net	81,795			94,024			81,605			83,407
Inventories	430			555
Inventory							100			158
Income taxes receivable	33,020			32,709			2,303			2,679
Prepaid expenses and other current assets	16,631			14,910			18,283			17,969
Total current assets	163,067			183,991			131,543			146,802
Equipment and improvements, net	26,683			25,790			27,832			27,426
Capitalized software costs, net	13,827			13,250			17,948			13,607
Deferred income taxes, net	8,158			8,198			12,266			11,265
Intangibles, net	85,943			91,675			79,165			69,213
Goodwill	188,837			188,837			202,272			185,898
Other assets	18,559			19,049			18,883			19,010
Total assets	$	505,074		$	530,790		$	489,909		$	473,221

LIABILITIES AND SHAREHOLDERS’ EQUITY
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	4,122		$	11,126		$	5,007		$	4,618
Deferred revenue	54,361			57,935			51,471			52,383
Accrued compensation and related benefits	14,257			18,670			14,388			24,513
Income taxes payable	90			91			2,265			405
Other current liabilities	52,660			50,238			32,618			46,775
Total current liabilities	125,490			138,060			105,749			128,694
Deferred revenue, net of current	1,476			1,335			1,438			1,394
Deferred compensation	6,617			6,357			6,386			6,629
Line of credit	88,000			105,000			45,000			15,000
Other noncurrent liabilities	13,365			10,661			17,148			16,461
Total liabilities	234,948			261,413			175,721			168,178
Commitments and contingencies (Note 13)
Shareholders’ equity:
Common Stock
$0.01 par value; authorized 100,000 shares; issued and outstanding 61,510 and 60,978 shares at June 30, 2016 and March 31, 2016, respectively	615			610
Shareholders' equity:
Common stock
$0.01 par value; authorized 100,000 shares; issued and outstanding 63,370 and 62,455 shares at June 30, 2017 and March 31, 2017, respectively							634			625
Additional paid-in capital	212,765			211,262			233,742			228,549
Accumulated other comprehensive loss	(593		)	(481		)	(372		)	(358		)
Retained earnings	57,339			57,986
Total shareholders’ equity	270,126			269,377
Total liabilities and shareholders’ equity	$	505,074		$	530,790
Retained earnings ⁽¹⁾							80,184			76,227
Total shareholders' equity							314,188			305,043
Total liabilities and shareholders' equity							$	489,909		$	473,221

⁽¹⁾ Includes cumulative-effect adjustment related to the adoption of ASU 2016-09, as defined in Note 1. See Note 1 for additional details.

The accompanying notes are an integral part of these consolidated financial statements.

QUALITY SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME ~~(LOSS)~~

(In thousands, except per share data)

(Unaudited)


	Three Months Ended June 30,						Three Months Ended June 30,
	2016			2015			2017			2016
Revenues:
Software license and hardware	$	14,789		$	16,189		$	12,800		$	14,789
Software related subscription services	19,875			12,246			23,906			19,875
Total software, hardware and related	34,664			28,435			36,706			34,664
Support and maintenance	38,007			43,713			41,116			38,007
Revenue cycle management and related services	21,053			20,243			21,403			21,053
Electronic data interchange and data services	22,124			20,189			23,312			22,124
Professional services	6,357			9,584			8,385			6,357
Total revenues	122,205			122,164			130,922			122,205
Cost of revenue:
Software license and hardware	7,120			7,041			5,373			7,120
Software related subscription services	9,087			5,958			10,430			9,087
Total software, hardware and related	16,207			12,999			15,803			16,207
Support and maintenance	6,568			7,943			7,623			6,568
Revenue cycle management and related services	14,231			14,512			15,361			14,231
Electronic data interchange and data services	12,763			12,326			13,158			12,763
Professional services	7,046			8,197			7,224			7,046
Total cost of revenue	56,815			55,977			59,169			56,815
Gross profit	65,390			66,187			71,753			65,390
Operating expenses:
Selling, general and administrative	40,581			39,171			42,977			40,581
Research and development costs, net	18,224			17,085			19,989			18,224
Amortization of acquired intangible assets	2,704			897			2,047			2,704
Restructuring costs	3,753			—			—			3,753
Total operating expenses	65,262			57,153			65,013			65,262
Income from operations	128			9,034			6,740			128
Interest income	8			302			9			8
Interest expense	(1,013		)	—			(677		)	(1,013		)
Other expense, net	(87		)	(50		)	(22		)	(87		)
Income (loss) before provision for (benefit of) income taxes	(964		)	9,286			6,050			(964		)
Provision for (benefit of) income taxes	(317		)	2,924			2,154			(317		)
Net income (loss)	$	(647	)	$	6,362		$	3,896		$	(647	)
Other comprehensive income (loss):
Foreign currency translation, net of tax	(122		)	(72		)	(14		)	(122		)
Unrealized gain (loss) on marketable securities, net of tax	10			(4		)
Unrealized gain on marketable securities, net of tax							—			10
Comprehensive income (loss)	$	(759	)	$	6,286		$	3,882		$	(759	)
Net income (loss) per share:
Basic	$	(0.01	)	$	0.11		$	0.06		$	(0.01	)
Diluted	$	(0.01	)	$	0.10		$	0.06		$	(0.01	)
Weighted-average shares outstanding:
Basic	61,179			60,312			62,636			61,179
Diluted	61,179			61,064			62,643			61,179
Dividends declared per common share	$	—		$	0.175

The accompanying notes are an integral part of these consolidated financial statements.

QUALITY SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Three Months Ended June 30,						Three Months Ended June 30,
	2016			2015			2017			2016
Cash flows from operating activities:
Net income (loss)	$	(647	)	$	6,362		$	3,896		$	(647	)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	2,554			2,279			2,774			2,554
Amortization of capitalized software costs	2,371			2,439			1,271			2,371
Amortization of other intangibles	5,732			1,800			5,448			5,732
Amortization of debt issuance costs	269			—			269			269
Loss on disposal of equipment and improvements	40			—			16			40
Provision for bad debts	762			575			2,091			762
Provision for inventory obsolescence	130			57			20			130
Share-based compensation	1,259			684			2,041			1,259
Deferred income taxes	40			81			—			40
Excess tax deficiency from share-based compensation							420			—
Change in fair value of contingent consideration	2,574			403			—			2,574
Restructuring costs, net of amounts paid	1,308			—
Restructuring costs							—			1,308
Changes in assets and liabilities, net of amounts acquired:
Accounts receivable	11,467			7,120			1,546			11,467
Inventories	(5		)	(82		)
Inventory							38			(5		)
Accounts payable	(7,029		)	887			(841		)	(7,029		)
Deferred revenue	(3,433		)	(4,557		)	(1,102		)	(3,433		)
Accrued compensation and related benefits	(5,721		)	(8,406		)	(10,245		)	(5,721		)
Income taxes	(423		)	(7,140		)	2,157			(423		)
Deferred compensation	260			635			(243		)	260
Other assets and liabilities	1,425			570			3,238			1,425
Net cash provided by operating activities	12,933			3,707			12,794			12,933
Cash flows from investing activities:
Additions to capitalized software costs	(2,948		)	(3,635		)	(5,248		)	(2,948		)
Additions to equipment and improvements	(3,462		)	(3,337		)	(2,471		)	(3,462		)
Proceeds from sales and maturities of marketable securities	9,291			1,120			—			9,291
Purchases of marketable securities	—			(1,514		)
Payments for acquisitions, net of cash acquired							(33,856		)	—
Net cash provided by (used in) investing activities	2,881			(7,366		)	(41,575		)	2,881
Cash flows from financing activities:
Proceeds from line of credit							30,000			—
Principal repayments on line of credit	(17,000		)	—			—			(17,000		)
Proceeds from issuance of shares under employee plans	359			225			3,970			359
Dividends paid	—			(10,700		)
Net cash used in financing activities	(16,641		)	(10,475		)
Net increase (decrease) in cash and cash equivalents	(827		)	(14,134		)
Payment of contingent consideration related to acquisitions							(18,817		)	—
Cancellation of shares related to tax withholdings for vesting of equity awards							(708		)	—
Net cash provided by (used in) financing activities							14,445			(16,641		)
Net decrease in cash and cash equivalents							(14,336		)	(827		)
Cash and cash equivalents at beginning of period	27,176			118,993			37,673			27,176
Cash and cash equivalents at end of period	$	26,349		$	104,859		$	23,337		$	26,349

QUALITY SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS – (Continued)

(In thousands)

(Unaudited)


	Three Months Ended June 30,				Three Months Ended June 30,
	2016		2015		2017		2016
Supplemental disclosures of cash flow information:
Cash paid during the period for income taxes, net of refunds	$	65	$	9,661
Cash paid for income taxes					$	157	$	146
Cash refunds from income taxes					579		81
Cash paid for interest	$	736	$	—	411		736
Non-cash investing and financing activities:
Tenant improvement allowance from landlord	$	3,094	$	—	$	980	$	3,094
Dividends declared but not paid	—		10,703
Unpaid additions to equipment and improvements	$	25	$	190	591		25



On April 14, 2017, we acquired Entrada, Inc. in a transaction summarized as follows:
Fair value of net assets acquired	$	35,293		$	—
Cash paid, net of cash acquired	(33,856		)	—
Liabilities assumed	$	1,437		$	—

The accompanying notes are an integral part of these consolidated financial statements.

QUALITY SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except shares and per share data)

(Unaudited)

1. Summary of Significant Accounting Policies

Principles of Consolidation. The consolidated financial statements include the accounts of Quality Systems, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Each of the terms “we,” “us,” or “our” as used herein refers collectively to the Company, unless otherwise stated. All intercompany accounts and transactions have been eliminated.

Business Segments. We have determined that the Company operates in one segment as of June 30, 2017. We have made such determination by first identifying our Chief Executive Officer as our chief operating decision maker ("CODM") and considering the measures used by our CODM to allocate resources. Our CODM utilizes consolidated revenue and consolidated operating results to assess performance and make decisions about allocation of resources.

Previously, through the end of fiscal year 2017, we operated under two reportable segments, consisting of the Software and Related Solutions segment and the RCM and Related Services segment, which was consistent with the disaggregated financial information used and evaluated by our CODM to assess performance and make decisions about the allocation of resources. However, as part of our reorganization efforts that were substantially complete as of the end of fiscal year 2017, our internal organizational structure whereby certain functions that formerly existed within each individual operating segment has continued to evolve. Our former Chief Operating Officer was previously responsible for leading the operations of our former RCM and Related Services business while our former Chief Client Officer led our client success organization, consisting of the Software and Related Solutions business and other functions, such as sales and marketing. Upon the resignation of our former Chief Operating Officer in April 2017 and concurrent appointment of our former Chief Client Officer as Chief Operating Officer, our entire portfolio of software and services were aligned under our new Chief Operating Officer in an effort to provide our clients with an even more simplified experience and more effectively deliver a consolidated financial solution to our clients, rather than components of a solution. As a result of such changes in our internal organization structure, the CODM now operates the Company as a single functional organization. The CODM measures company-wide performance by reviewing consolidated revenue and operating results and evaluates the impact of allocating resources to overall profit and margins on a consolidated basis.

Basis of Presentation. The accompanying unaudited consolidated financial statements as of June 30, ~~2016~~2017 and for the three months ended June 30, ~~2016~~2017 have been prepared in accordance with the requirements of Quarterly Report on Form 10-Q and Article 10 of the Securities and Exchange Commission Regulation S-X and therefore do not include all information and notes which would be presented were such consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in our Annual Report on Form 10-K for the fiscal year ended March 31, ~~2016.~~2017. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair statement of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year.

References to amounts in the consolidated financial statement sections are in thousands, except shares and per share data, unless otherwise specified.

Significant Accounting Policies. There have been no material changes to ~~the~~our significant accounting policies from those disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, ~~2016.~~2017.

Share-Based Compensation. The following table shows total share-based compensation expense included in the consolidated statements of comprehensive income for the three months ended June 30, ~~2016~~2017 and ~~2015:~~2016:


	Three Months Ended June 30,						Three Months Ended June 30,
	2016			2015			2017			2016
Costs and expenses:
Cost of revenue	$	149		$	97		$	137		$	149
Research and development costs, net	83			110			361			83
Selling, general and administrative	1,027			477			1,543			1,027
Total share-based compensation	1,259			684			2,041			1,259
Income tax benefit	(412		)	(200		)	(716		)	(412		)
Decrease in net income	$	847		$	484		$	1,325		$	847

Recent Accounting Standards. Recent accounting pronouncements requiring implementation in future periods are discussed below or in the notes, where applicable.

In ~~March~~May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09, Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting ("ASU 2017-09"). ASU 2017-09 clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early application is permitted and prospective application is required. ASU 2017-09 is effective for us in the first quarter of fiscal 2019, and we currently do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). ASU 2017-04 removes the requirement to compare the implied fair value of goodwill with its carrying amount as part of Step two of the goodwill impairment test. Instead, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019, and early adoption is permitted on goodwill impairment tests performed on testing dates after January 1, 2017. ASU 2017-04 is effective for us in the fourth quarter of fiscal 2020, and we currently do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). ASU 2017-01 clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted in two scenarios as identified in the new standard. ASU 2017-01 is effective for us in the first quarter of fiscal 2019, and we currently do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In November 2016, the FASB issued Accounting Standards Update ("ASU") 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”).ASU 2016-18 provides guidance on the classification of restricted cash and cash equivalents in the statement of cash flows. Although it does not provide a definition of restricted cash or restricted cash equivalents, it states that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. ASU 2016-18 is effective for us in the first quarter of fiscal 2019, and we do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In October 2016, the FASB issued ASU 2016-16, Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). ASU 2016-16 requires the recognition of current and deferred income taxes for intra-entity asset transfers when the transaction occurs. ASU 2016-16 is effective for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. ASU 2016-16 is effective for us in the first quarter of fiscal 2019, and we are currently in the process of evaluating the potential impact of adoption of this updated authoritative guidance on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to add and clarify guidance on the classification of certain cash receipts and cash payments in the statement of cash flows to eliminate diversity in practice related to how such cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. ASU 2016-15 is effective for us in the first quarter of fiscal 2019, and we do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). ASU 2016-09 simplifies the accounting for and reporting on share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for interim and annual reporting periods beginning after December 15, 2016, with early adoption permitted. The amendments in this update are to be applied differently upon adoption with certain amendments being applied prospectively, retrospectively and under a modified retrospective transition method. We ~~are currently~~adopted ASU 2016-09 in the ~~process~~first quarter of ~~evaluating~~fiscal 2018. As permitted by ASU 2016-09, we have made an accounting policy election to account for forfeitures as they occur, which was adopted on a modified retrospective basis and resulted in a cumulative-effect adjustment of $0.1 million to retained earnings and additional paid-in capital as of April 1, 2017. ASU 2016-09 also eliminates additional paid-in capital pools and requires excess tax benefits and tax deficiencies to be recorded in the ~~potential~~income statement when the awards vest or are settled, which was adopted on a prospective basis. The requirements to recognize previously unrecognized excess tax benefits on a modified retrospective basis did not have an impact ~~of adoption of this updated authoritative guidance~~ on our consolidated financial statements. Upon adoption of ASU 2016-09, excess tax benefits and tax deficiencies are recognized in the income statement, and the tax effects of exercised or vested awards are treated as discrete items in the period they occur. The provisions of ASU 2016-09 could have an impact to our future income tax expense, including increased volatility in our effective tax rate on a quarter by quarter basis due to a number of factors, including fluctuations in the stock price and the timing of stock option exercises and vesting of restricted share

awards. Additionally, ASU 2016-09 addresses presentation of excess tax benefits and deficiencies and employee taxes paid related to shares withheld for tax withholdings purposes on the statement of cash flows, including a requirement to present excess tax benefits and deficiencies as an operating activity in the same manner as other cash flows related to income taxes on the statement of cash flows, which will be adopted on a prospective basis, and presentation of employee taxes paid related to shares withheld for tax withholdings purposes as a financing activity, which is consistent with our current presentation and thus did not impact our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which is intended to improve financial reporting about leasing transactions. The new guidance will require ~~entities that lease assets~~lessees to recognize on their balance sheets the assets and liabilities for the rights and obligations created by ~~those~~ leases and to disclose key information about the leasing arrangements. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. ASU 2016-02 is effective for us in the first quarter of fiscal ~~2019.~~2020. We are currently in the process of evaluating the potential impact of adoption of this updated authoritative guidance ~~on our consolidated financial statements.~~

~~In July 2015, the FASB issued ASU 2015-11,~~ ~~Simplifying the Measurement of Inventory~~ ~~("ASU 2015-11"), which replaces the concept of subsequently measuring inventory at 'lower of cost or market' with that of 'lower of cost and net realizable value'. The~~

guidance only applies to inventories for which cost is determined by methods other than last-in first-out (LIFO) and the retail inventory method (RIM). ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years. Early adoption is permitted. This guidance is effective for us for fiscal year ending March 31, 2018. We do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

~~In April 2015, the FASB issued ASU 2015-05,~~ ~~Customer’s Accounting for Fees Paid in a Cloud Arrangement~~ ("ASU 2015-05"), which requires a customer to determine whether a cloud computing arrangement contains a software license that should be accounted for as internal-use software or as a service contract. ASU 2015-05 is effective for interim and annual reporting periods beginning after December 15, 2015, with early adoption permitted. Upon adoption, an entity has the option to apply the provisions of ASU 2015-05 either prospectively to all arrangements entered into or materially modified, or retrospectively. The adoption of this new standard did not have material impact on our consolidated financial statements.

~~In August 2014, the FASB issued ASU 2014-15,~~ ~~Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern~~ ("ASU 2014-15"), which incorporates and expands upon certain principles that currently exist in U.S. auditing standards. ASU 2014-15 provides guidance regarding management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The new standard requires management to perform interim and annual evaluations and sets forth principles for considering the mitigating effect of management's plans. The standard mandates certain disclosures when conditions give rise to substantial doubt about a company’s ability to continue as a going concern within one year from the financial statement issuance date. ASU 2014-15 is effective for annual reporting periods ending after December 15, 2016, and all annual and interim periods thereafter. Early adoption is permitted. ASU 2014-15 is effective for us for fiscal year ending March 31, 2017. We do not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

In May 2014, the FASB, along with the International Accounting Standards Board, issued ASU 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards and GAAP. The core principle of this updated guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard also requires additional disclosure about revenue and provides improved guidance for multiple element arrangements. ~~ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, based on the~~In July 2015 decision, ~~and issuance of~~the FASB issued ASU 2015-14, Deferral of Effective Date ("ASU 2015-14") ~~by the FASB~~ to delay the effective date by one year. ~~Companies are permitted to adopt this new guidance following either a full retrospective or modified retrospective approach.~~ In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606) –Principal versus Agent Consideration ("ASU 2016-08"). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing ("ASU 2016-10”). In May 2016, the FASB issued ASU 2016-11, Revenue from Contracts with Customers (Topic 606) and Derivatives and Hedging (Topic 815) – Rescission of SEC Guidance Because of ASU 2014-09 and 2014-16 ("ASU 2016-11") and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) –Narrow Scope Improvements and Practical Expedients ("ASU 2016-12"). The new ASUs do not change the core principle of the guidance in Topic 606 (as amended by ASU 2014-09), but rather help to provide further interpretive clarifications on the new guidance in ASU 2014-09. ASU 2014-09, as amended by ASU 2015-14, is effective for us in the first quarter of fiscal 2019. Companies are permitted to adopt this new guidance following either a full retrospective or modified retrospective approach.

We ~~are~~have performed an initial assessment of the potential impacts to our business processes, systems, and internal controls that could result from the implementation of the new revenue standard. Based on our initial assessment, we currently inbelieve that the impact on our consolidated financial statements could be material. We expect that revenue related to hardware, EDI, maintenance, and certain subscriptions would remain substantially unchanged, and we are the process of evaluating the ~~potential~~ impact of ~~implementation~~the new revenue standard on our other revenue streams. A significant amount of work remains as we continue to evaluate all potential impacts of the ~~updated authoritative guidance on~~new revenue standard, and develop and implement the necessary changes to our current accounting systems, processes, and internal controls. Accordingly, our preliminary assessments are subject to change. We expect that the new revenue standard will result in additional complexity to our revenue recognition, including an increased amount of significant judgments and estimates as compared to our current revenue recognition. We currently expect to implement the new revenue standard when it becomes effective for us in the first quarter of fiscal 2019 utilizing the modified retrospective transition method. Under this transition method, prior period amounts will not be adjusted and the cumulative effect from prior periods of applying the new revenue standard will be recognized in our consolidated ~~financial statements.~~balance sheets as of the date of adoption, including an adjustment to retained earnings.

We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

2. Fair Value Measurements

The following tables set forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis at June 30, ~~2016~~2017 and March 31, ~~2016:~~2017:


	Balance at		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)		Balance at			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)
	June 30, 2016				June 30, 2017												Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)
ASSETS
Cash and cash equivalents⁽¹⁾	$	26,349	$	26,349		Significant Other Observable Inputs (Level 2)	$	—	Unobservable Inputs (Level 3)		$	—	$	23,337		$	23,337		$	—		$	—
Restricted cash and cash equivalents	4,842		4,842			—			—		5,915			5,915			—			—
	$	31,191	$	31,191		$	—		$	—	$	29,252		$	29,252		$	—		$	—
LIABILITIES
Contingent consideration related to acquisitions	$	26,417	$	—		$	—		$	26,417
	$	26,417	$	—		$	—		$	26,417


	Balance at		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)		Balance at			Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)
	March 31, 2016				March 31, 2017												Significant Other Observable Inputs (Level 2)			Unobservable Inputs (Level 3)
ASSETS
Cash and cash equivalents ⁽¹⁾	$	27,176	$	27,176		Significant Other Observable Inputs (Level 2)	$	—	Unobservable Inputs (Level 3)		$	—	$	37,673		$	37,673		$	—		$	—
Restricted cash and cash equivalents	5,320		5,320			—			—		4,916			4,916			—			—
Marketable securities ⁽²⁾	9,297		9,297			—			—
	$	41,793	$	41,793		$	—		$	—	$	42,589		$	42,589		$	—		$	—
LIABILITIES
Contingent consideration related to acquisitions	$	23,843	$	—		$	—		$	23,843
Contingent consideration related to acquisitions ⁽²⁾											$	18,817		$	—		$	18,817		$	—
	$	23,843	$	—		$	—		$	23,843	$	18,817		$	—		$	18,817		$	—

⁽¹⁾ Cash equivalents consist primarily of money market funds.

⁽²⁾~~Marketable securities consist of available-for-sale money market instruments and fixed-income securities, including certificates of deposit, corporate bonds and notes, and municipal securities.~~

~~Our~~ The contingent consideration ~~liabilities~~liability as of March 31, 2017 relates ~~primarily~~ to the ~~acquisitions~~acquisition of ~~Mirth and HealthFusion. We assess~~HealthFusion, which was settled during the ~~fair value of contingent consideration liabilities on a recurring basis and any adjustments to fair value subsequent to the~~quarter ended June 30, 2017. The measurement period are reflected in the consolidated statements of comprehensive income. Key assumptions include discount rates and probability-adjusted achievement estimates of certain revenue and strategic targets that are not observable in the market. The categorization of the framework used to measure fair value of the contingent consideration liability ~~is considered~~ended on December 31, 2016, and thus the actual revenue achievement rate was utilized to compute the ending contingent consideration liability as of March 31, 2017. Accordingly, the contingent consideration liability was reflected under a Level ~~3 due to~~2 valuation hierarchy because the ~~subjective nature~~fair value was determined based on other significant observable inputs.

We believe that the fair value of ~~the unobservable inputs used.~~

~~The following table presents activity in our~~other financial assets and liabilities, ~~measured at fair value using significant unobservable inputs (Level 3), as~~including accounts receivable, accounts payable, and line of ~~and for the three months ended June 30, 2016:~~

Total Liabilities
Balance as of March 31, 2016 $ 23,843
Fair value adjustments 2,574
Balance as of June 30, 2016 $ 26,417
credit, approximate their respective carrying values due to their nominal credit risk.

Non-Recurring Fair Value Measurements

We have certain assets, including goodwill and other intangible assets, which are measured at fair value on a non-recurring basis and are adjusted to fair value only if an impairment charge is recognized. The categorization of the framework used to measure fair value of the assets is considered to be within the Level 3 valuation hierarchy due to the subjective nature of the unobservable inputs used. ~~There were~~During the three months ended June 30, 2017, no adjustments ~~to fair value of such assets.~~were recorded.

3. Business Combinations

~~HealthFusion~~Entrada Acquisition

On ~~January 4, 2016,~~April 14, 2017, we completed our acquisition of ~~HealthFusion Holdings,~~Entrada, Inc. ("~~HealthFusion"~~Entrada") pursuant to the terms of the Agreement and Plan of Merger, dated April 11, 2017 (the ~~“Merger Agreement"~~"Agreement")~~, dated October 30, 2015. HealthFusion provides Web-based, cloud computing software for physicians, medical billing service providers, and hospitals. Its flagship product, MediTouch®,~~. Based in Nashville, TN, Entrada is a ~~fully-integrated,~~leading provider of cloud-based ~~software suite consisting~~solutions that are reshaping the way care is delivered by leveraging the power of ~~clearinghouse, practice management,~~mobile whenever and wherever care happens. Entrada’s best-in-class mobile application integrates with multiple clinical platforms and all major electronic health ~~records,~~record systems. Entrada enables organizations to maximize their existing technology investments while simultaneously enhancing physician and ~~patient portals with rich functionality to enable mobility, workflow automation, and advanced reporting and analytics aimed primarily at small-to-mid-size physician practices.~~staff productivity. The acquisition of ~~HealthFusion~~Entrada and its cloud-based, mobile application is part of our ~~strategy~~commitment to ~~expand~~deliver systematic solutions that meet its ~~client base~~clients' transforming work requirements to become increasingly nimble and ~~cloud-based solution capabilities in the ambulatory market. Over time, we plan to expand the HealthFusion platform to satisfy the needs of practices of increasing size and complexity.~~mobile.

The preliminary purchase price totaled ~~$183,049,~~$33,958, which ~~includes~~included preliminary working capital and other customary adjustments and the fair value of contingent consideration related to an additional $25,000 of cash in the form of an earnout, subject to HealthFusion achieving certain revenue targets through December 31, 2016. The initial estimated fair value of contingent consideration of $16,700 was estimated using a Monte Carlo-based valuation model that considered, among other assumptions and inputs, our estimate of projected HealthFusion revenues.

adjustments. The acquisition was ~~initially~~primarily funded by a draw against ~~the~~our revolving credit agreement (see Note 7)~~, a portion of which was subsequently repaid from existing cash on hand.~~.

We accounted for the ~~HealthFusion~~Entrada acquisition as a purchase business combination using the acquisition method of accounting. The preliminary purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their preliminary estimated fair values as of the acquisition date. The preliminary fair values of acquired assets and liabilities assumed represent management’s estimate of fair value and are subject to change if additional information, such as changes to deferred taxes and/or working capital, becomes available. We expect to finalize the purchase price allocation as soon as practicable within the measurement period, but not later than one year following the acquisition date.

The preliminary estimated fair value of the acquired tangible and intangible assets and liabilities assumed were determined using multiple valuation approaches depending on the type of tangible or intangible asset acquired, including but not limited to the income approach, the excess earnings method and the relief from royalty method approach.

In connection with the Entrada acquisition, we recorded $15,400 of intangible assets related to customer relationships, trade names and software technology. We are amortizing the Entrada customer relationships over 10 years and trade names and software technology over 5 years. The weighted average amortization period for the total amount of intangible assets acquired is 6.1 years.

The preliminary amount of goodwill represents the excess of the preliminary purchase price over the preliminary net identifiable assets acquired and liabilities assumed. Goodwill primarily represents, among other factors, the value of synergies expected to be

realized and the assemblage of all assets that enable us to create new client relationships, neither of which qualify as separate amortizable intangible assets. Goodwill arising from the acquisition of ~~HealthFusion was determined as the excess of the preliminary purchase price over the net acquisition date fair values of the acquired assets and the liabilities assumed, and~~Entrada is not deductible for tax purposes. ~~HealthFusion operates under the NextGen Division.~~

The total preliminary purchase price for the ~~HealthFusion~~Entrada acquisition is summarized as follows:


Initial purchase price	$	165,000	$	34,000
Contingent consideration	16,700
Preliminary working capital and other adjustments	1,349		(42		)
Total preliminary purchase price	$	183,049	$	33,958


	January 4, 2016			April 14, 2017
Preliminary fair value of the net tangible assets acquired and liabilities assumed:
Acquired cash and cash equivalents	$	2,225		$	102
Accounts receivable, net	1,514			1,835
Prepaid expenses and other current assets	4,645
Prepaid expense and other current assets				145
Equipment and improvements, net	767			134
Capitalized software costs, net	307			364
Other assets	700
Deferred income taxes, net				1,041
Accounts payable	(1,085		)	(639		)
Accrued compensation and related benefits	(533		)	(120		)
Deferred revenue	(1,067		)
Deferred income taxes, net	(12,027		)
Deferred revenues				(234		)
Other liabilities	(2,721		)	(444		)
Total preliminary net tangible assets acquired and liabilities assumed	(7,275		)	2,184
Preliminary fair value of identifiable intangible assets acquired:
Goodwill				16,374
Software technology	42,500			10,500
Customer relationships	28,500			3,300
Trade name	4,000			1,600
Goodwill	115,324
Total preliminary identifiable intangible assets acquired	190,324			31,774
Total preliminary purchase price	$	183,049		$	33,958

The pro forma effects of the Entrada acquisition would not have been material to the Company's results of operations and are therefore not presented.

4. Goodwill

We test goodwill for impairment annually during our first fiscal quarter, referred to as the annual test date. Based on our assessment, we have determined that there was no impairment to goodwill as of June 30, 2017. We will also test for impairment between annual test dates if an event occurs or circumstances change that would indicate the carrying amount may be impaired. ~~Impairment testing for~~

As part of our annual goodwill impairment test, we first assess qualitative factors to determine whether it is ~~performed at a reporting-unit level, which is defined as an operating segment or one level below an operating segment (referred to as a component). A component~~more likely than not that the fair value of ~~an operating segment is~~ a reporting unit ifis less than its carrying amount. The qualitative assessment includes consideration of factors such as margin of fair values of the ~~component constitutes~~reporting units as of the most recent quantitative impairment assessment compared to the relative carrying value of net assets for each reporting unit and the potential adverse changes in fair value since the most recent quantitative impairment assessment by considering changes in macroeconomic variables, changes in the industry in which we operate, and relevant company- and reporting unit-specific factors. If we conclude that it is more likely than not that the fair value of a ~~business for which discrete financial information~~reporting unit is ~~available and segment management regularly reviews the operating results of that component.~~

~~During the quarter ended June 30, 2016,~~less than its carrying amount, we ~~elected to bypass the optional qualitative~~conduct a two-step quantitative goodwill impairment test. The first step of the ~~goodwill~~ impairment ~~assessment, as permitted by~~test involves comparing the ~~authoritative guidance, and proceed directly~~fair values of the applicable reporting units with ~~the quantitative step, under which we compared the estimated fair value of each reporting unit with goodwill to its net~~their carrying ~~amount. An impairment loss, if any, is recognized when~~values. If the carrying amount of the reporting ~~unit's net assets~~unit exceeds the ~~estimated~~reporting unit's fair value, we perform the second step of the goodwill impairment test. The second step of the goodwill impairment test involves comparing the implied fair value of the affected reporting ~~unit. We determined~~unit's goodwill with the carrying value of that goodwill. The amount by which the carrying value of the goodwill exceeds its implied fair value, if any, is recognized as an impairment loss. As of June 30, 2017, our qualitative assessment indicated that it was more likely than not that the fair value of ~~our~~all reporting units by considering two valuation methods, consisting of the income approach (based upon estimates of future discounted cash flows for each reporting unit) and a market comparable approach (based upon valuation multiples of companies that operate in similar industries with similar operating characteristics). The net cash flows used to determine fair value under the income approach represent our best estimate of projected operating results and assumed terminal growth rates, which are dependent on a number of significant assumptions, including historical experience, expectations of future performance, and expected changes to the macroeconomic variables and industry in which the Company operates, and are subject to changes given the inherent uncertainty in predicting future results. We also considered the Company's stock price and market capitalization as a corroborative step in assessing the reasonableness of the fair values estimated for the reporting units as part of the goodwill impairment assessment. The results of the goodwill impairment assessment established that the fair value for each reporting unit with goodwill ~~significantly~~ exceeded its respective net carrying ~~amount, indicating that no goodwill~~values and, therefore, additional impairment ~~existed as of the annual test date.~~testing was not deemed necessary.

We do not amortize goodwill as it has been determined to have an indefinite useful life. The carrying amount of goodwill was $202,272 and $185,898 as of June 30, 2017 and March 31, 2017, respectively.

~~Goodwill by reporting unit consists of the following:~~

June 30,
2016 March 31,
2016
NextGen Division $ 149,258
$ 149,258
RCM Services Division 32,290
32,290
QSI Dental Division ⁽¹⁾
7,289
7,289
Total goodwill $ 188,837
$ 188,837

⁽¹⁾QSI Dental Division goodwill is presented on a basis consistent with that of our management reporting structures. However, for the purposes of our annual assessment of goodwill for impairment and as otherwise may be required, the QSI Dental Division goodwill is allocated to the reporting units that derive cash flows from the products associated with the acquired goodwill. For all periods presented in this report, the allocation resulted in substantially all of the QSI Dental Division goodwill being ascribed to the NextGen Division.

5. Intangible Assets

Our definite-lived intangible assets, other than capitalized software development costs, are summarized as follows:


	June 30, 2016												June 30, 2017
	Customer Relationships			Trade Name and Contracts			Software Technology			Total			Customer Relationships			Trade Name and Contracts			Software Technology			Total
Gross carrying amount	$	50,550		$	7,368		$	67,810		$	125,728		$	53,850		$	7,080		$	78,310		$	139,240
Accumulated amortization	(22,043		)	(3,174		)	(14,568		)	(39,785		)	(30,685		)	(2,422		)	(26,968		)	(60,075		)
Net intangible assets	$	28,507		$	4,194		$	53,242		$	85,943		$	23,165		$	4,658		$	51,342		$	79,165


	March 31, 2016												March 31, 2017
	Customer Relationships			Trade Name and Contracts			Software Technology			Total			Customer Relationships			Trade Name and Contracts			Software Technology			Total
Gross carrying amount	$	50,550		$	7,370		$	67,810		$	125,730		$	50,550		$	5,480		$	67,810		$	123,840
Accumulated amortization	(19,618		)	(2,895		)	(11,542		)	(34,055		)	(28,972		)	(2,088		)	(23,567		)	(54,627		)
Net intangible assets	$	30,932		$	4,475		$	56,268		$	91,675		$	21,578		$	3,392		$	44,243		$	69,213

Amortization expense related to customer relationships and trade name and contracts recorded as operating expenses in the consolidated statements of comprehensive income was ~~$2,704~~$2,047 and ~~$897~~$2,704 for the three months ended June 30, ~~2016~~2017 and ~~2015,~~2016, respectively. Amortization expense related to software technology recorded as cost of revenue was ~~$3,027~~$3,401 and ~~$903~~$3,027 for the three months ended June 30, ~~2016~~2017 and ~~2015,~~2016, respectively.

The following table ~~represents~~summarizes the remaining estimated amortization of definite-lived intangible assets as of June 30, ~~2016:~~2017:


			Amortization Expense Recorded As:
			Operating Expense		Cost of Revenue		Total
For the year ended March 31,
2017 (remaining nine months)	$	16,729
2018	19,115
2018 (remaining nine months)			5,839		10,464		16,303
2019	16,703		5,502		13,951		19,453
2020	15,706		4,505		13,951		18,456
2021	10,974		3,656		10,068		13,724
2022 and beyond	6,716
2022			2,518		2,280		4,798
2023 and beyond			5,803		628		6,431
Total	$	85,943	$	27,823	$	51,342	$	79,165

6. Capitalized Software Costs

Our capitalized software costs are summarized as follows:


	June 30, 2016			March 31, 2016			June 30, 2017			March 31, 2017
Gross carrying amount	$	99,648		$	96,699		$	110,560		$	104,948
Accumulated amortization	(85,821		)	(83,449		)	(92,612		)	(91,341		)
Net capitalized software costs	$	13,827		$	13,250		$	17,948		$	13,607

Amortization expense related to capitalized software costs was ~~$2,371~~$1,271 and ~~$2,439~~$2,371 for the three months ended June 30, 2017 and 2016, respectively, and ~~2015, respectively.~~is recorded as cost of revenue in the consolidated statements of comprehensive income.

The following table presents the remaining estimated amortization of capitalized software costs as of June 30, ~~2016.~~2017. The estimated amortization is comprised of (i) amortization of released products and (ii) the expected amortization for products that are not yet available for sale based on their estimated economic lives and projected general release dates.


For the year ended March 31,
2017 (remaining nine months)	$	5,300
2018	3,900
2018 (remaining nine months)			$	5,800
2019	3,100		7,200
2020	1,527		3,300
2021	—		1,648
2022 and beyond	—
Total	$	13,827	$	17,948

7. Line of Credit

On January 4, 2016, we entered into a $250,000 revolving credit agreement (“Credit Agreement”) with JP Morgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and certain other lenders. The ~~credit agreement~~Credit Agreement is secured by substantially all of our existing and future property and material domestic subsidiaries. The Credit Agreement provides a subfacility of up to $10,000 for letters of credit and a subfacility of up to $10,000 for swing-line loans. The Credit Agreement matures on January 4, 2021 and the full balance of the revolving loans and all other obligations under the agreement must be paid at that time. The revolving loans under the Credit Agreement will be available for letters of credit, working capital and general corporate purposes. We were in compliance with all covenants under the Credit Agreement as of June 30, ~~2016.~~2017.

As of June 30, ~~2016,~~2017, we had ~~$88,000~~$45,000 in outstanding loans and ~~$162,000~~$205,000 of unused credit under the Credit Agreement. ~~During~~As of March 31, 2017, we had $15,000 in outstanding loans under the Credit Agreement.

Interest expense related to the Credit Agreement was $407 and $740 for the three months ended June 30, 2017 and 2016, ~~we recorded $740 of interest expense and $269 in amortization~~respectively. Amortization of deferred debt issuance costs ~~related to~~was $269 for both the ~~Credit Agreement.~~three months ended June 30, 2017 and 2016.

8. Composition of Certain Financial Statement Captions

Accounts receivable may include amounts invoiced ~~but not yet rendered~~for undelivered products and services at each period end. Undelivered products and services are included as a component of the deferred revenue balance on the accompanying consolidated balance sheets.


	June 30, 2016			March 31, 2016			June 30, 2017			March 31, 2017
Accounts receivable, gross	$	93,266		$	104,467		$	90,366		$	93,377
Sales return reserve	(8,434		)	(7,541		)	(6,694		)	(7,213		)
Allowance for doubtful accounts	(3,037		)	(2,902		)	(2,067		)	(2,757		)
Accounts receivable, net	$	81,795		$	94,024		$	81,605		$	83,407

~~Inventories are summarized as follows:~~

June 30,
2016 March 31,
2016
Computer systems and components $ 430
$ 555
Inventory is comprised of computer systems and components.

Prepaid expenses and other current assets are summarized as follows:


	June 30, 2016		March 31, 2016		June 30, 2017		March 31, 2017
Prepaid expenses	$	11,530	$	11,804	$	15,694	$	14,884
Other current assets	5,101		3,106		2,589		3,085
Prepaid expenses and other current assets	$	16,631	$	14,910	$	18,283	$	17,969

Equipment and improvements are summarized as follows:


	June 30, 2016			March 31, 2016			June 30, 2017			March 31, 2017
Computer equipment	$	32,514		$	32,213		$	22,848		$	22,014
Internal-use software	10,201			10,201			12,168			13,053
Furniture and fixtures	11,304			9,799			11,762			10,472
Leasehold improvements	12,995			13,408			17,078			16,360
	67,014			65,621
Equipment and improvements, gross							63,856			61,899
Accumulated depreciation and amortization	(40,331		)	(39,831		)	(36,024		)	(34,473		)
Equipment and improvements, net	$	26,683		$	25,790		$	27,832		$	27,426

The current portion of deferred ~~revenue~~revenues are summarized as follows:


	June 30, 2016		March 31, 2016		June 30, 2017		March 31, 2017
Professional services	$	22,013	$	23,128	$	22,257	$	21,889
Software license, hardware and other	15,095		14,913		12,391		12,680
Support and maintenance	11,052		11,902		8,499		9,691
Software related subscription services	6,201		7,992		8,324		8,123
Deferred revenue, current	$	54,361	$	57,935
Deferred revenue					$	51,471	$	52,383

Accrued compensation and related benefits are summarized as follows:


	June 30, 2016		March 31, 2016		June 30, 2017		March 31, 2017
Payroll, bonus and commission					$	5,297	$	15,836
Vacation	$	8,585	$	8,987	9,091		8,677
Payroll, bonus and commission	5,672		9,683
Accrued compensation and related benefits	$	14,257	$	18,670	$	14,388	$	24,513

Other current and ~~non-current~~noncurrent liabilities are summarized as follows:


	June 30, 2016		March 31, 2016		June 30, 2017		March 31, 2017
Contingent consideration and other liabilities related to acquisitions	$	26,417	$	24,153
Care services liabilities	4,842		5,339		$	5,915	$	4,957
Customer credit balances and deposits	4,801		4,123		4,477		4,124
Accrued consulting and outside services					2,560		2,496
Deferred rent and lease obligations					2,417		2,427
Accrued EDI expense	2,405		2,382		2,276		2,490
Accrued royalties	2,390		2,341		2,021		2,033
Self insurance reserve	1,742		1,862
Accrued self insurance expense					1,996		1,697
Accrued outsourcing costs	1,609		1,604		1,787		1,588
Deferred rent	1,308		828
Accrued consulting and outside services	1,197		3,650
Accrued hosting costs					1,772		401
Accrued conferences and advertising costs					1,136		234
Accrued legal expense	819		864		1,056		853
Employee benefit plan withholdings					761		739
Sales tax payable					597		448
Contingent consideration and other liabilities related to acquisitions					—		18,817
Other accrued expenses	5,130		3,092		3,847		3,471
Other current liabilities	$	52,660	$	50,238	$	32,618	$	46,775

Deferred rent	$	9,281	$	6,577
Uncertain tax position and related liabilities	4,084		4,084
Deferred rent and lease obligations					$	11,749	$	11,402
Uncertain tax positions					5,103		4,762
Other liabilities					296		297
Other noncurrent liabilities	$	13,365	$	10,661	$	17,148	$	16,461

9. Income Taxes

The provision for income taxes for the three months ended June 30, 2017 was $2,154 and the benefit of income taxes for the three months ended June 30, 2016 was ~~$317~~$317. The effective tax rates were 35.6% and ~~the provision for income taxes~~32.9% for the three months ended June 30, ~~2015 was $2,924. The effective tax rates were 32.9%~~2017 and ~~31.5% for the three months ended June 30,~~ 2016, ~~and 2015,~~ respectively. The effective rate for the three months ended June 30, ~~2016~~2017 increased compared to the prior year period primarily due to ~~lower qualifying production activity deductions,~~the impact of share-based compensation shortfall expense in current period, offset by a favorable benefit in current period of state taxes and exclusion of certain non-deductible acquisition-related costs. Additionally, we adopted ASU 2016-09 (see Note 1), which requires excess tax expense and benefits to be recorded in the income statement. (income tax expense and/or benefit). Prior to adoption of ASU 2016-09, such amounts were recorded to additional paid-in capital and did not impact of the ~~research and development credit.~~effective tax rate.

The deferred tax assets and liabilities have been shown net in the accompanying consolidated balance sheets as noncurrent. We expect to receive the full benefit of the deferred tax assets recorded with the exception of certain state credits, ~~and~~ state net operating loss carryforwards, and foreign accumulated minimum tax credits, for which we have recorded a valuation allowance.

Uncertain tax positions

We had ~~a liability~~liabilities of ~~$3,955~~$5,103 and ~~$3,955~~$4,762 for unrecognized tax benefits related to various federal, state and local income tax matters as of June 30, ~~2016~~2017 and March 31, ~~2016,~~2017, respectively. If recognized, this amount would reduce our effective tax rate.

We are no longer subject to U.S. federal income tax examinations for tax years before ~~2012.~~fiscal years ended 2014. With a few exceptions, we are no longer subject to state or local income tax examinations for tax years before ~~2011.~~fiscal years ended 2013. We do not anticipate that total unrecognized tax benefits will significantly change due to the settlement of audits or the expiration of statute of limitations within the next twelve months.

10. Earnings ~~(Loss)~~ per Share

The dual presentation of “basic” and “diluted” earnings ~~(loss)~~ per share ~~(“EPS”)~~ is provided below. Share amounts below are in thousands.


	Three Months Ended June 30,					Three Months Ended June 30,
	2016			2015		2017		2016
Earnings (loss) per share — Basic:
Earnings per share — Basic:
Net income (loss)	$	(647	)	$	6,362	$	3,896	$	(647	)
Weighted-average shares outstanding — Basic	61,179			60,312		62,636		61,179
Net income (loss) per common share — Basic	$	(0.01	)	$	0.11	$	0.06	$	(0.01	)

Earnings (loss) per share — Diluted:
Earnings per share — Diluted:
Net income (loss)	$	(647	)	$	6,362	$	3,896	$	(647	)
Weighted-average shares outstanding	61,179			60,312		62,636		61,179
Effect of potentially dilutive securities	—			752		7		—
Weighted-average shares outstanding — Diluted	61,179			61,064		62,643		61,179
Net income (loss) per common share — Diluted	$	(0.01	)	$	0.10	$	0.06	$	(0.01	)

The computation of diluted net income ~~(loss)~~ per share does not include ~~2,767~~2,568 and ~~1,768~~2,767 options to acquire shares of common stock for the three months ended June 30, ~~2016~~2017 and ~~2015,~~2016, respectively, because their inclusion would have an anti-dilutive effect on net income per share.

11. Share-Based Awards

Employee Stock Option and Incentive Plans

In October 2005, our shareholders approved a stock option and incentive plan (the “2005 Plan”) under which 4,800,000 shares of common stock were reserved for the issuance of awards, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, performance shares, performance units (including performance options) and other share-based awards. The 2005 Plan provides that our employees and directors may, at the discretion of the Board of Directors ("Board") or a duly designated compensation committee, be granted certain share-based awards. In the case of option awards granted under the 2005 Plan, the exercise price of each option is determined based on the date of grant and expire no later than 10 years from the date of grant. Awards granted pursuant to the 2005 Plan are subject to the vesting schedule or performance metrics set forth in the agreements pursuant to which they are granted. Upon a change of control of our Company, as such term is defined in the 2005 Plan, awards under the 2005 Plan will fully vest under certain circumstances. The 2005 Plan expired on May 25, 2015. As of June 30, ~~2016,~~2017, there were ~~1,358,931~~759,185 outstanding options ~~and 25,046 outstanding shares of restricted stock, restricted stock units and performance based restricted stock~~ under the 2005 Plan.

In August 2015, our shareholders approved a stock option and incentive plan (the “2015 Plan”) under which 11,500,000 shares of common stock were reserved for the issuance of awards, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock awards and restricted stock unit awards, performance stock awards and other share-based awards. The 2015 Plan provides that our employees and directors may, at the discretion of the Board of Directors or a duly designated compensation committee, be granted certain share-based awards. In the case of option awards granted under the 2015 Plan, the exercise price of each option is determined based on the date of grant and expire no later than 10 years from the date of grant. Awards granted pursuant to the 2015 Plan are subject to the vesting schedule or performance metrics set forth in the agreements pursuant to which they are granted. Upon a change of control of our Company, as such term is defined in the 2015 Plan, awards under the 2015 Plan will fully vest under certain circumstances. As of June 30, ~~2016,~~2017, there were ~~1,856,500~~1,964,375 outstanding options, ~~664,532~~1,497,033 outstanding shares of restricted stock awards, 114,916 outstanding shares of performance stock awards, and ~~8,613,425~~6,026,095 shares available for future grant under the 2015 Plan.

~~A summary of~~The following table summarizes the stock option transactions during the three months ended June 30, ~~2016 follows:~~2017:

Number of
Shares

Weighted-
Average
Exercise
Price
per Share

Weighted-
Average
Remaining
Contractual
Life (years)

Aggregate
Intrinsic
Value
(in thousands)
Outstanding, April 1, 2016 2,447,286
$ 19.55
6.3 574
Granted 856,500
12.87
7.9

Forfeited/Canceled (88,355 ) 21.80
4.8

Outstanding, June 30, 2016 3,215,431
$ 17.59
5.8 $ 238
Vested and expected to vest, June 30, 2016 2,358,931
$ 17.59
5.8 $ 238
Exercisable, June 30, 2016 773,346
$ 26.19
2.3 $ 143



	Number of Shares		Weighted- Average Exercise Price per Share		Weighted- Average Remaining Contractual Life (years)	Aggregate Intrinsic Value (in thousands)
Outstanding, April 1, 2017	2,885,415		$	15.41	6.2	$	3,150
Granted	309,000		16.02		7.9
Exercised	(214,105	)	16.63		6.5	$	116
Forfeited/Canceled	(256,750	)	16.21		5.7
Outstanding, June 30, 2017	2,723,560		$	16.62	6.1	$	7,652
Vested and expected to vest, June 30, 2017	2,438,142		$	16.87	6.0	$	5,459
Exercisable, June 30, 2017	889,205		$	20.99	4.6	$	1,185

We utilize the Black-Scholes valuation model for estimating the fair value of share-based compensation with the following assumptions:


			Three Months Ended June 30,
	Three Months Ended June 30,		2017	2016
	2016	2015
Expected term	6.0 years	3.8 years	5.6 - 5.7 years	6.0 years
Expected volatility	37.4%	38.3%	37.6% - 37.7%	37.4%
Expected dividends	—%	4.1%	—%	—%
Risk-free rate	1.5%	1.6%	1.9%	1.5%

The weighted-average grant date fair value of stock options granted during the three months ended June 30, 2017 and 2016 was $6.12 and ~~2015 was~~ $4.92 ~~and $3.67~~ per share, respectively.

During the three months ended June 30, ~~2016,~~2017, a total of ~~856,500~~309,000 options to purchase shares of common stock were granted under the 2015 Plan at an exercise price equal to the market price of our common stock on the date of grant, as summarized below:

Option Grant Date Number of Shares Exercise Price
Vesting Terms ⁽¹⁾
Expiration
May 31, 2016 100,000
$ 12.71
Five years May 31, 2024
May 25, 2016 216,500
$ 12.78
Four years May 25, 2024
May 24, 2016 540,000
$ 12.93
Four years May 24, 2024
Total 856,500



Option Grant Date	Number of Shares	Exercise Price		Vesting Terms ⁽¹⁾	Expiration
June 13, 2017	249,000	$	16.37	Four years	June 13, 2025
May 24, 2017	60,000	$	14.57	Four years	May 24, 2025
Total	309,000

⁽¹⁾ Options vest in equal annual installments on each grant anniversary date commencing one year following the date of grant.

Non-vested stock option award activity during the three months ended June 30, ~~2016~~2017 is summarized as follows:


	Non-Vested Number of Shares		Weighted- Average Grant-Date Fair Value per Share		Non-Vested Number of Shares		Weighted- Average Grant-Date Fair Value per Share
Outstanding, April 1, 2016	1,859,750		$	4.67
Outstanding, April 1, 2017					2,073,295		$	5.09
Granted	856,500		4.92		309,000		6.12
Vested	(226,845	)	5.96		(353,690	)	5.02
Forfeited/Canceled	(47,320	)	4.53		(194,250	)	4.63
Outstanding, June 30, 2016	2,442,085		$	4.64
Outstanding, June 30, 2017					1,834,355		$	4.92

As of June 30, ~~2016, $10,226~~2017, $8,184 of total unrecognized compensation costs related to stock options is expected to be recognized over a weighted-average period of ~~4.0~~3.3 years. This amount does not include the cost of new options that may be granted in future periods or any changes in our forfeiture percentage. The total fair value of options vested during the three months ended June 30, 2017 and 2016 was $1,776 and ~~2015 was~~ $1,353, ~~and $1,657,~~ respectively.

Restricted stock awards activity during the three months ended June 30, 2017 is summarized as follows:



	Number of Shares		Weighted- Average Grant-Date Fair Value per Share
Outstanding, April 1, 2017	902,948		$	12.92
Granted	757,631		15.43
Vested	(129,197	)	12.78
Canceled	(34,349	)	12.86
Outstanding, June 30, 2017	1,497,033		$	14.29

Share-based compensation expense related to restricted stock awards was $1,539 and $545 for the three months ended June 30, 2017 and 2016, respectively.

The weighted-average grant date fair value for the restricted stock awards was estimated using the market price of the common stock on the date of grant. The fair value of the restricted stock awards is amortized on a straight-line basis over the vesting period, which is generally two to three years.

As of June 30, 2017, $18,519 of total unrecognized compensation costs related to restricted stock awards is expected to be recognized over a weighted-average period of 2.4 years. This amount does not include the cost of new restricted stock awards that may be granted in future periods.

On December 29, 2016, the Compensation Committee of the Board granted 123,082 performance stock awards to certain executive officers, of which 114,916 shares are currently outstanding. The performance stock awards vest in four equal increments on each of the first four anniversaries of the grant date, subject in each case to the executive officer’s continued service and achievement of certain Company performance goals, including strong Company stock price performance. Share-based compensation expense related to the performance stock awards was $73 for the three months ended June 30, 2017.

Employee Share Purchase Plan

On August 11, 2014, our shareholders approved an Employee Share Purchase Plan (the “Purchase Plan”) under which 4,000,000 shares of common stock were reserved for future grant. The Purchase Plan allows eligible employees to purchase shares through payroll deductions of up to 15% of total base salary at a price equal to 90% of the lower of the fair market values of the shares as of the beginning or the end of the corresponding offering period. Any shares purchased under the Purchase Plan are subject to a six-month holding period. Employees are limited to purchasing no more than 1,500 shares on any single purchase date and no more than $25,000 in total fair market value of shares during any one calendar year. As of June 30, ~~2016,~~2017, we have issued ~~147,464~~238,622 shares under the Purchase Plan and ~~3,852,536~~3,761,378 shares are available for future issuance.

Share-based compensation expense recorded for the employee share purchase plan was $97 and $126 for the three months ended June 30, 2017 and 2016, ~~and $68 for the three months ended June 30, 2015.~~

~~Restricted Stock Awards~~

~~Restricted stock awards activity during the three months ended June 30, 2016 is summarized as follows:~~

Number of
Shares

Weighted-
Average
Grant-Date
Fair Value
per Share
Outstanding, April 1, 2016 191,247
$ 14.44
Granted 498,898
12.79
Vested (567 ) 20.20
Outstanding, June 30, 2016 689,578
$ 13.24

~~Share-based compensation expense related to restricted stock awards was $545 for the three months ended June 30, 2016 and $198 for the three months ended June 30, 2015.~~

As of June 30, 2016, $7,928 of total unrecognized compensation costs related to restricted stock awards is expected to be recognized over a weighted-average period of 2.6 years. This amount does not include the cost of new restricted stock awards that may be granted in future periods.respectively.

12. Concentration of Credit Risk

We had cash deposits at U.S. banks and financial institutions which exceeded federally insured limits at June 30, ~~2016.~~2017. We are exposed to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, we do not anticipate non-performance by these institutions.

13. Commitments, Guarantees and Contingencies

Commitments and Guarantees

Our software license agreements include a performance guarantee that our software products will substantially operate as described in the applicable program documentation for a period of 365 days after delivery. To date, we have not incurred any significant costs associated with our performance guarantee or other related warranties and do not expect to incur significant warranty costs in the future. Therefore, no accrual has been made for potential costs associated with these warranties. Certain arrangements also include performance guarantees related to response time, availability for operational use, and other performance-related guarantees. Certain arrangements also include penalties in the form of maintenance credits should the performance of the software fail to meet the performance guarantees. To date, we have not incurred any significant costs associated with these warranties and do not expect to incur significant warranty costs in the future. Therefore, no accrual has been made for potential costs associated with these warranties.

We have historically offered short-term rights of return in certain sales arrangements. If we are able to estimate returns for these types of arrangements and all other criteria for revenue recognition have been met, revenue is recognized and these arrangements are recorded in the consolidated financial statements. If we are unable to estimate returns for these types of arrangements, revenue is not recognized in the consolidated financial statements until the rights of return expire, provided also, that all other criteria of revenue recognition have been met.

Certain standard sales agreements contain a money back guarantee providing for a performance guarantee that is already part of the software license agreement as well as training and support. The money back guarantee also warrants that the software will

remain robust and flexible to allow participation in the federal health incentive programs. The specific elements of the performance guarantee pertain to aspects of the software, which we have already tested and confirmed to consistently meet using our existing software without any modifications or enhancements. To date, we have not incurred any costs associated with this guarantee and do not expect to incur significant costs in the future. Therefore, no accrual has been made for potential costs associated with this guarantee.

Our standard sales agreements contain an indemnification provision pursuant to which we shall indemnify, hold harmless, and reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any United States patent, any copyright or other intellectual property infringement claim by any third-party with respect to our software. As we have not incurred any significant costs to defend lawsuits or settle claims related to these indemnification agreements, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these indemnification obligations.

Hussein Litigation

On October 7, 2013, a complaint was filed against our Company and certain of our officers and directors in the Superior Court of the State of California for the County of Orange, captioned Ahmed D. Hussein v. Sheldon Razin, Steven Plochocki, Quality Systems, Inc. and Does 1-10, inclusive, No. 30-2013-00679600-CU-NP-CJC, by Ahmed Hussein, a former director and significant shareholder of our Company. We filed a demurrer to the complaint, which the ~~court~~Court granted on April 10, 2014. An amended complaint was filed on April 25, 2014. The amended complaint generally alleges fraud and deceit, constructive fraud, negligent misrepresentation and breach of fiduciary duty in connection with statements made to our shareholders regarding our financial condition and projected future performance. The amended complaint seeks actual damages, exemplary and punitive damages and costs. We filed a demurrer to the amended complaint. On July 29, 2014, the ~~court~~Court sustained the demurrer with respect to the breach of fiduciary duty claim, and overruled the demurrer with respect to the fraud and deceit claims. On August 28, 2014, we filed an answer and also filed a cross-complaint against the plaintiff, alleging that the plaintiff breached fiduciary duties owed to the Company, Mr. Razin and Mr. Plochocki. Mr. Razin and Mr. Plochocki have dismissed their claims against Hussein, leaving QSI as the sole plaintiff in the cross-complaint. On June 26, 2015, we filed a motion for summary judgment, which the ~~court~~Court granted on September 16, 2015, dismissing all claims against us. On September 23, 2015, the plaintiff filed an application for reconsideration of the Court's summary judgment order, which the ~~court~~Court denied. On October 28, 2015, the plaintiff filed a motion for summary judgment, seeking to dismiss our cross-complaint, which the ~~court~~Court denied on March 3, 2016. On May 9, 2016, the plaintiff filed a motion for summary adjudication, seeking to again dismiss our cross-complaint, which the Court denied on August 5, 2016. On August 5, 2016, the plaintiff filed a motion for judgment on the pleadings, seeking to again dismiss our cross-complaint, which the Court denied on September 2, 2016. Trial on our cross-complaint began June 12, 2017. On July 26, 2017, the Court issued a statement of decision granting Hussein’s motion for judgment on our cross-complaint. ~~The hearing for~~We believe the ~~motion is set for August 4, 2016.~~Court’s decision on our cross-complaint was erroneous and we are evaluating a potential appeal. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Federal Securities Class Action

On November 19, 2013, a putative class action complaint was filed on behalf of the shareholders of our Company other than the defendants against us and certain of our officers and directors in the United States District Court for the Central District of California by one of our shareholders. After the ~~court~~Court appointed lead plaintiffs and lead counsel for this action, and recaptioned the action In re Quality Systems, Inc. Securities Litigation, No. 8L13-cv-01818-CJC(JPRx), lead plaintiffs filed an amended complaint on April 7, 2014. The amended complaint, which is substantially similar to the litigation described above under the caption “Hussein Litigation,” generally alleges that statements made to our shareholders regarding our financial condition and projected future performance were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the individual defendants are liable for such statements because they are controlling persons under Section 20(a) of the Exchange Act. The complaint seeks compensatory damages, court costs and attorneys' fees. We filed a motion to dismiss the amended complaint on June 20, 2014, which the ~~court~~Court granted on October 20, 2014, dismissing the complaint with prejudice. Plaintiffs filed a motion for reconsideration of the Court's order, which the ~~court~~Court denied on January 5, 2015. On January 30, 2015, Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit, captioned In re Quality Systems, Inc. Securities Litigation, No. 15-55173. ~~Plaintiffs filed their opening brief and we answered.~~ Oral argument ~~is not yet scheduled.~~was held on December 5, 2016. On July 28, 2017, the Ninth Circuit issued a decision reversing and remanding the District Court's order on our motion to dismiss. We believe that the plaintiffs' claims are without merit and continue to defend against them ~~vigorously.~~vigorously, including by evaluating potential challenges to the Ninth Circuit decision. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Shareholder Derivative Litigation

gross mismanagement by our directors, in addition to unjust enrichment and insider selling by individual directors. The complaint seeks compensatory damages, restitution and disgorgement of all profits, court costs, attorneys’ fees and implementation of enhanced corporate governance procedures. The parties have agreed to stay this litigation until the United States Court of Appeals for the Ninth Circuit issues a ruling on the pending appeal described above under the caption “Federal Securities Class ~~Action”.~~Action,” and will meet and confer to discuss process going forward. We believe that the plaintiff’s claims are without merit and intend to defend against them vigorously. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Other Regulatory Matters

In April 2017, we received a request for documents and information from the U.S. Attorney's Office for the District of Vermont pursuant to a Civil Investigative Demand (“CID”). The CID relates to an investigation concerning the certification we obtained for our software under the U.S. Department of Health and Human Services' Electronic Health Record Incentive Program. Given the highly-regulated nature of our industry, we may, from time to time, be subject to subpoenas, requests for information, or investigations from various government agencies. It is our practice to respond to such matters in a cooperative, thorough and timely manner. We are currently responding to this CID and intend to cooperate fully with the government. Requests and investigations of this nature may lead to the assertion of claims or the commencement of legal proceedings against us, as well as other material liabilities. In addition, our responses to the CID require time and effort, which can result in additional cost to us. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

14. ~~Operating Segment Information~~

As of June 30, 2016, we have three reportable segments that are evaluated regularly by our chief operating decision maker (consisting of our Chief Executive Officer) in deciding how to allocate resources and in assessing performance.

~~Operating segment data is as follows:~~

Three Months Ended June 30,
2016 2015
Revenue:
NextGen Division $ 95,556
$ 91,615
RCM Services Division 22,365
22,462
QSI Dental Division 4,284
4,418
Hospital Solutions Division ⁽¹⁾
—
3,669
Consolidated revenue $ 122,205
$ 122,164

Operating income:

NextGen Division $ 45,649
$ 44,858
RCM Services Division 4,458
4,417
QSI Dental Division 1,877
950
Hospital Solutions Division ⁽¹⁾
—
955
Corporate and unallocated (51,856 ) (42,146 )
Consolidated operating income $ 128
$ 9,034

⁽¹⁾ ~~The former Hospital Solutions Division was divested in October 2015.~~

~~Assets by segment are not tracked or used by our chief operating decision maker to allocate resources or to assess performance, and thus not included in the table above.~~

~~The major components of the corporate and unallocated amounts are summarized in the table below:~~

Three Months Ended June 30,
2016 2015
Research and development costs, net $ 18,224
$ 17,085
Amortization of capitalized software costs 2,371
2,439
Marketing expense 2,943
3,816
Restructuring costs (see Note 15) 3,753
—
Other corporate and overhead costs ⁽¹⁾
24,565
18,806
Total corporate and unallocated $ 51,856
$ 42,146

⁽¹⁾ The net increase in other corporate and overhead costs in the three months ended June 30, 2016 is primarily related to higher amortization of acquired intangible assets and other general and administrative costs associated with the acquisition of HealthFusion, higher acquisition costs (including fair value adjustments to contingent consideration liabilities), and higher professional services costs.

The amounts classified as corporate and unallocated consist primarily of corporate general and administrative costs, acquisition and transaction-related costs, amortization of acquired intangible assets, amortization of capitalized software costs, and costs of other centrally managed overhead and shared-services functions, including accounting and finance, human resources, information services, marketing, legal, and research and development, that are not controlled by segment level leadership. Although the segments may derive direct benefits as a result of such costs, our chief operating decision maker evaluates performance based upon stand-alone segment operating income, which excludes these corporate and unallocated amounts.

~~15.~~ Restructuring Plan

In fiscal year 2016, we initiated a three-phase plan intended to better position our organization for future success. We implemented a series of actions to with the objective of achieving greater synergies and further integration of our products and services in support of our business strategies, and enabling a more efficient, integrated and client-centered delivery of the holistic solutions that we believe is required by our ambulatory care clients. We also transformed our management team with the appointment of a new chief executive officer, chief financial officer, chief technology officer, and chief client officer. In the first phase, we redesigned the organization to more effectively support the execution of our strategy. Under phase twoas part of our reorganization ~~we will continue building and enhancing the capabilities to drive future revenue growth. The third phase of the plan will consist of developing the services and solutions to accelerate revenue growth.~~

The overall plan also includes a multi-year initiative, called NextGen 2.0, to merge our business units into a single, streamlined, functional-based organization structure and to realign our organizational structure by consolidating the sales, marketing, information services, and software development responsibilities into single, company-wide roles in order to achieve greater efficiency. As a result, our future reportable segments may change due to such changes in the organization of our business.

The first phase was completed in April 2016, when we announced a corporate restructuring plan, which was approved by our Board of Directors. Under the restructuring plan, we reduced our domestic headcount by approximately 150 employees, or approximately six percent of our U.S.-based workforce. During the three months ended June 30, 2016,efforts, we recorded ~~$3,753~~$7,078 of restructuring costs within operating expenses in our consolidated statements of net income and comprehensive income. The restructuring plan was substantially complete by the end of fiscal 2017. The restructuring costs ~~consist~~consisted primarily of payroll-related costs, such as severance, outplacement costs, and continuing healthcare coverage, associated with the involuntary separation of employees pursuant to a one-time benefit arrangement, which were accrued when it was probable that the benefits ~~will~~would be paid and the ~~amount~~amounts were reasonably estimable. Also included in restructuring costs were certain facilities-related costs associated with accruals for the remaining lease obligations at certain locations, including Solana Beach, Costa Mesa, and a portion of Horsham with contractual lease terms ending between January 2018 and September 2023. We have vacated each of the locations or portions thereof and are actively marketing the locations for sublease. We estimated the remaining lease obligations at fair value as of the cease-use date for each location based on the future contractual lease obligations, reduced by projected sublease rentals that could be reasonably obtained for the locations after a period of marketing, and adjusted for the effect deferred rents that have been recognized under the lease. The effect of discounting future cash flows using a credit-adjusted risk free rate was not significant. Sublease income and commencement dates were estimated based on data available from rental activity in the local markets. Significant judgment was required to estimate the remaining lease obligations at fair value and actual results could vary from the estimates, resulting in potential future adjustments to amounts previously recorded. As of June 30, ~~2016,~~2017, the remaining lease obligation, net of estimated projected sublease rentals, was $1,932.

15. Subsequent Events

On July 31, 2017, we ~~had~~entered into an Agreement and Plan of Merger (the “Agreement”) to acquire EagleDream Health Inc. (“EagleDream Health”), a ~~remaining liability~~cloud-based analytics company that drives meaningful insight across clinical, financial and administrative data to optimize practice performance. Based in Rochester, NY, EagleDream Health empowers organizations with intuitive analytics and actionable intelligence to achieve successful population health management. Our acquisition of ~~$1,308 related~~EagleDream Health will enable us to ~~our restructuring costs, which we expect~~enhance the care experience and increase patient engagement for ambulatory clinics and health systems while reducing the per capita cost of healthcare and improving the work-life balance for clinicians and staff. The transaction is expected to ~~settle~~close promptly upon the satisfaction of customary closing conditions and will be settled in ~~the second quarter~~all cash with a value of ~~fiscal 2017. The restructuring plan was substantially completed as of June 30, 2016.~~approximately $26,000.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q ("Report") and certain information incorporated herein by reference contain forward-looking statements within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Report, other than statements that are purely historical, are forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “should,” “would,” “could,” “may,” and similar expressions also identify forward-looking statements. These forward-looking statements include, without limitation, discussions of our product development plans, business strategies, future operations, financial condition and prospects, developments in and the impacts of government regulation and legislation, including, without limitation, The American Recovery and Reinvestment Act, the Patient Protection and Affordable Care Act, and the Medicare Access and CHIP Reauthorization Act of 2015, and market factors influencing our results. Our expectations, beliefs, objectives, intentions and strategies regarding our future results are not guarantees of future performance and are subject to risks and uncertainties, both foreseen and unforeseen, that could cause actual results to differ materially from results contemplated in our forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to continue to develop new products and increase systems sales in markets characterized by rapid technological evolution, consolidation, and competition from larger, better-capitalized competitors. Many other economic, competitive, governmental and technological factors could affect our ability to achieve our goals, and interested persons are urged to review any risks that may be described in “Item 1A. Risk Factors” as set forth herein and other risk factors appearing in our most recent Annual Report on Form 10-K for the fiscal year ended March 31, ~~2016~~2017 (“Annual Report”), as supplemented by additional risk factors, if any, in our interim filings on our Quarterly Reports on Form 10-Q, as well as in our other public disclosures and filings with the Securities and Exchange Commission ("SEC"). Because of these risk factors, as well as other variables affecting our financial condition and results of operations, past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. We assume no obligation to update any forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Report.

This management's discussion and analysis of financial condition and results of operations ("MD&A") is provided as a supplement to the consolidated financial statements and notes thereto included elsewhere in this Report in order to enhance your understanding of our results of operations and financial condition and should be read in conjunction with, and is qualified in its entirety by, the consolidated financial statements and related notes thereto included elsewhere in this Report. Historical results of operations, percentage margin fluctuations and any trends that may be inferred from the discussion below are not necessarily indicative of the operating results for any future period.

Company Overview

Quality Systems, Inc., ~~primarily through its~~known to our clients as NextGen Healthcare, ~~subsidiary,~~ provides ~~technology-based~~software, services and analytics solutions ~~and services~~ to the ambulatory care ~~market in~~market. We are a healthcare information technology and services company that delivers the ~~United States. Our solutions provide our clients with the ability~~foundational capabilities to ~~redesign patient care and other workflow processes while improving productivity through the facilitation of managed access~~organizations that want to ~~patient information. We help~~ promote healthy ~~communities by empowering~~communities. Our technology provides a customizable platform that empowers physician practice success, ~~and enriching~~enriches the patient care experience ~~while lowering~~and lowers the cost of healthcare.

We primarily derive revenue by developing and marketing software and services that automate certain aspects of practice management (“PM”) and electronic health records (“EHR”) for ~~medical~~ambulatory care practices. In addition, our software and ~~dental practices.~~services facilitate interoperability. Our software can be licensed ~~on a perpetual,~~and delivered on-premise ~~basis, hosted in a private cloud~~ or in ~~certain instances,~~the cloud as a software-as-a-service (“SaaS”) ~~solution.~~. Our services include maintenance and support, professional services, and complementary services such as managed cloud services, revenue cycle management (“RCM”) and electronic data interchange (“EDI”). We market and sell our solutions through a dedicated sales force and to a much lesser extent, through resellers. Our clients ~~include~~span the entire ambulatory market from large multi-specialty to small single specialty practices and ~~small practice physicians,~~include networks of practices such as physician hospital organizations (“PHOs”), management service organizations (“MSOs”), accountable care organizations (“ACOs”), ambulatory care centers and community health centers and medical and dental schools. We also provide implementation, training, support and maintenance for software and complementary services such as revenue cycle management (“RCM”) and electronic data interchange (“EDI”).centers.

We have ~~a history~~determined that the Company operates in one segment as of ~~developing new and enhanced technologies. Over the course~~June 30, 2017. Refer to Note 1, "Summary of ~~a number~~Significant Accounting Policies" of ~~years, we have also made strategic acquisitions~~our notes to ~~complement and enhance our product portfolio~~consolidated financial statements included elsewhere in ~~the ambulatory care, RCM, and hospital markets.~~this Report for additional information.

Quality Systems, Inc. was incorporated in California in 1974. Our principal offices are located at 18111 Von Karman Ave., Suite 800, Irvine, California, 92612. Our websites are located at ~~www.Nextgen.com~~www.nextgen.com and www.qsii.com. We operate on a fiscal year ending on March 31.

Trends and Events in Our Business

We believe that the following trends and events as described below have contributed to our consolidated results of operations and may continue to impact our future results.

We believe healthcare is more heavily influenced by regulatory and national health projects than by the cycles of our economy. The healthcare industry has been significantly impacted by the Obama Administration's broad healthcare reform efforts, including the Health Information Technology for Economic and Clinical Health portion of the American Recovery and Reinvestment Act of 2009 ("HITECH Act") and the Patient Protection and Affordable Care Act ("ACA") that provided significant incentives to health care organizations for "Meaningful Use" adoption and interoperable electronic health record solutions.

We also believe that healthcare reform, including the repeal of the sustainable growth rate ~~("SGR")~~(SGR) formula as part of the Medicare Access and CHIP Reauthorization Act of 2015 ("MACRA"), and a movement towards a value-based, pay-for-performance model and quality initiative efforts will stimulate demand for robust electronic health record solutions as well as new health information technology solutions from bundled billing capabilities to patient engagement and population health management. We believe MACRA may be the most important of the three regulations for our market because it permanently changes how ambulatory healthcare providers are reimbursed by Medicare. It offers certainty and a timeline for the market’s move away from volume-based, fee-for-service models to value-based payment models that reward the delivery of lower cost, high quality care.

While we expect to benefit from the increasing demands for greater efficiency as well as government support for increased adoption of electronic health records, the market for physician based electronic health records software is becoming increasingly saturated while physician group practices are rapidly being consolidated by hospitals, insurance payers and other entities. Hospital software providers are leveraging their position with their hospital clients to gain market share with hospital owned physician practices. Insurance providers and large physician groups are also consolidating physician offices creating additional opportunity for ambulatory software providers like us. Our strategy is to focus on addressing the growing needs of accountable care organizations around interoperability, patient engagements, population health, and data analytics.

We believe that our core strength lies in the central role our software products and services play in the delivery of healthcare by the primary physician in an ambulatory setting. We intend to remain at the forefront of upcoming new regulatory requirements and meaningful use requirements for stimulus payments. We intend to continue the development and enhancement of our software solutions to support healthcare reform, such as the recently enacted MACRA, which promotes the transition from fee-for-service to value-based, pay-for-performance and patient-centric and quality initiatives such as accountable care organizations. Key elements of our future software development will be to expand our interoperability capabilities enhancing the competitiveness of our software offerings, make our products more intuitive and easy to use, and to enhance the capability of our MediTouch® Platform to allow us to deliver our software over the cloud to larger ambulatory care practices.

We have a history of enhancing our solutions through both organic and inorganic activities. Over the last few years, we have entered into strategic transactions to complement and enhance our product portfolio in the ambulatory care market. In addition to the activities described above, mergers and acquisitions have been important to our development. In September 2013 we acquired Mirth Corporation ("Mirth"), a global leader in health information technology that helps clients achieve interoperability. In AprilOctober 2015, we ~~acquired Gennius, Inc. ("Gennius"), a population health analytics company which we believe enhances and leverages~~divested our ~~acquisition of Mirth by broadening our business intelligence capabilities in the growing population health and value based care areas.~~former Hospital Solutions division. In January 2016, we ~~completed the acquisition of~~acquired HealthFusion Holdings, Inc. ("HealthFusion")~~, a cloud-based healthcare information technology (“HCIT”) company providing electronic health record (“EHR”)~~ and practice management (“PM”) software primarily to the one-to-ten physician size market. We entered into a revolving credit agreement to fund the transaction. We believe the acquisition provided us with access to a market we were not in and provides us with technology that will accelerate our transition to the cloud.

We continue to evaluate the organizational structure of our company with the objective of achieving greater synergies and further integration of our products and services, in support of our business strategies. In fiscal 2016, we initiated a three-phase plan to better position our organization for future success. In the first phase, we redesigned the organization to more effectively support the execution of our strategy. We also transformed our management team with the appointment of a new chief executive officer, chief financial officer, chief technology officer, and chief client officer. This first phase was completed in April ~~2016, when~~2017, we announced a corporate restructuring plan intended to enable a more efficient, integrated and client-centered delivery of the holistic solutions that we believe is required by our ambulatory care clients. The restructuring plan includes merging our business units into a single, streamlined, functional-based organization structure. We are now beginning phase two of our reorganization, which includes building and enhancing the capabilities that will drive future revenue growth. The third phase of the plan will consist of developing the services and solutions to accelerate revenue growth.acquired Entrada, Inc. ("Entrada").

We have and intend to continue investments in our infrastructure, including but not limited to maintaining and expanding sales, marketing and product development activities to improve patient care and reduce healthcare costs, providing industry-leading, integrated clinical and administrative healthcare data systems, services, and expertise to clinical, medical, technology, and healthcare business professionals while continuing our strong commitment of service in support of our client satisfaction programs. These investments in our infrastructure will continue while maintaining reasonable expense discipline. We strive to add new clients and expand our relationship with existing clients through delivery of add-on and complementary products and services and believe that our client base that is using our software on a daily basis is a strategic asset. We intend to leverage this strategic asset by expanding our product and service offerings towards this client base.

Led by our vision and mission, we are resetting our strategy and structure to deliver value to our clients. To achieve a lower-cost, increased capability structure, our new management team is building what we believe is an aligned, client-focused organization, supported by a recurring revenue stream and a large and diverse existing client base.

Our Strategy

We strive to be the trusted partner for clients of all ~~size,~~sizes, integrating services ~~software~~ and ~~analytics~~software into a consolidated ~~solution.~~solution that enables an efficient and effective caregiver and patient experience while driving positive financial outcomes. As a healthcare information technology and services company, we plan to continue investing in our current capabilities as well as building and/or acquiring new capabilities as we guide our clients through an evolving healthcare marketplace that is transitioning from fee-for-service to fee-for-value ~~payer~~ reimbursement models. With approximately 90,000 providers using our solutions, we are enabling care and believe we can truly transform the delivery of care through the following strategic priorities:

Focus on the ambulatory client segment. In October 2015, we sold our former Hospital Solutions ~~Division~~division to focus on our core ambulatory clients. Further, a recent operational reorganization better allows us to serve the needs of our ambulatory clients through a simpler, more nimble, and focused organization. We believe it is essential to protect, build and sell new capabilities within our ambulatory ~~platform.~~client segment. We are focused on our core by increasing quality and the serviceability of our solutions. We intend to continue to enhance the capabilities of our NextGen Ambulatory flagship product.

~~Cloud transition.~~ ~~Through our acquisition~~ At the same time, we intend to expand the capability of ~~HealthFusion in January 2016, we acquired a~~the highly scalable, pure cloud-based and mobile-enabled MediTouch® platform.

Platform as a service. With the introduction of our API 2.0 framework and our continued leverage of the Mirth interoperability platform, we will continue our evolution to plug and play extensibility and information sharing that ~~operates under~~allows our customers to innovate and deploy high-fidelity extensions to our core applications without the ~~tradename MediTouch®.~~costs, risks (security, performance, etc.) or complexity commonly associated with direct binding. We ~~intend~~have also introduced platform-enabled automation capabilities to expand the capability of this platform to serve the requirements of larger ambulatory practices. When combined with our Mirth-branded products, we can offer our clients a full suite of cloud-based solutions that better enableempower our clients to ~~focus on care delivery.~~

~~Solutions selling.~~drive cost out of their processes while supporting their needs to implement the highly personalized workflows that are required to support value based care. Our acquisition of Entrada and its cloud-based, mobile application in April 2017 demonstrates our commitment to innovation that becomes essential for practitioners by improving their clinical productivity with documentation support services that seamlessly integrate into their electronic health record. We believe there is significant opportunity to extend the solutions we offer existing and new clients through ~~value added~~value-added services such as RCM ~~EDI, interoperability solutions~~ and ~~professional services. This will evolve our relationships from being a seller of products and services to delivering a consistent solution suite and experience for our clients.~~EDI.

Population health software and services. We are migrating into applications, analytics and services that ~~we believe~~ will enable our clients to ~~be successful in managing~~proactively manage the health of patient populations. We are establishing strong development ~~partners within~~partnerships with our ~~core client base,~~most innovative customers who are actively participating in shared-risk contracts, and working together with them to ~~determine~~create progressive population health ~~solutions.~~

~~More effective use of capital.~~ ~~From cessation of the dividend, leveraging our balance sheet for future opportunities,~~capabilities. We support extraordinary information sharing capabilities vital to managing ~~our cost structure, we are transforming our capital strategy. Our recent reorganization was formulated to result in a more efficient, integrated and streamlined organization.~~patient populations through Mirth interoperability offerings.

Critical Accounting Policies and Estimates

The discussion and analysis of our consolidated financial statements and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect our reported amounts of assets, liabilities, revenue and expenses, and related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends, and other factors we believe to be reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. On a regular basis, we review the accounting policies and update our assumptions, estimates, and judgments, as needed, to ensure that our consolidated financial statements are presented fairly and in accordance with GAAP. Actual results could differ materially from our estimates under different assumptions or conditions. To the extent that there are material differences between our estimates and actual results, our financial condition or results of operations will be affected.

We describe our significant accounting policies in Note 2, “Summary of Significant Accounting Policies,” of our notes to consolidated financial statements included in our Annual Report. We discuss our critical accounting policies and estimates in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report. There have been no material changes in our significant accounting policies or critical accounting policies and estimates since the fiscal year ended March 31, ~~2016.~~2017.

Results of Operations

The following table sets forth the percentage of revenue represented by each item in our consolidated statements of comprehensive income for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016 (certain percentages below may not sum due to rounding):


	Three Months Ended June 30,				Three Months Ended June 30,
	2016		2015		2017		2016
Revenues:
Software license and hardware	12.1	%	13.3	%	9.8	%	12.1	%
Software related subscription services	16.3		10.0		18.3		16.3
Total software, hardware and related	28.4		23.3		28.0		28.4
Support and maintenance	31.1		35.8		31.4		31.1
Revenue cycle management and related services	17.2		16.6		16.3		17.2
Electronic data interchange and data services	18.1		16.5		17.8		18.1
Professional services	5.2		7.8		6.4		5.2
Total revenues	100.0		100.0		100.0		100.0
Cost of revenue:
Software license and hardware	5.8		5.8		4.1		5.8
Software related subscription services	7.4		4.9		8.0		7.4
Total software, hardware and related	13.3		10.6		12.1		13.3
Support and maintenance	5.4		6.5		5.8		5.4
Revenue cycle management and related services	11.6		11.9		11.7		11.6
Electronic data interchange and data services	10.4		10.1		10.1		10.4
Professional services	5.8		6.7		5.5		5.8
Total cost of revenue	46.5		45.8		45.2		46.5
Gross profit	53.5		54.2		54.8		53.5
Operating expenses:
Selling, general and administrative	33.2		32.1		32.8		33.2
Research and development costs, net	14.9		14.0		15.3		14.9
Amortization of acquired intangible assets	2.2		0.7		1.6		2.2
Restructuring costs	3.1		—		—		3.1
Total operating expenses	53.4		46.8		49.7		53.4
Income from operations	0.1		7.4		5.1		0.1
Interest income	—		0.2
Interest expense	(0.8	)	—		(0.5	)	(0.8	)
Other expense, net	(0.1	)	—		—		(0.1	)
Income (loss) before provision for (benefit of) income taxes	(0.8	)	7.6		4.6		(0.8	)
Provision for (benefit of) income taxes	(0.3	)	2.4		1.6		(0.3	)
Net income (loss)	(0.5	)%	5.2	%	3.0	%	(0.5	)%

Revenues

The following table presents our consolidated revenues for the three months ended June 30, ~~2016,~~2017 and ~~2015~~2016 (in thousands):


	Three Months Ended June 30,				Three Months Ended June 30,
	2016		2015		2017		2016
Revenues:
Software license and hardware	$	14,789	$	16,189	$	12,800	$	14,789
Software related subscription services	19,875		12,246		23,906		19,875
Total software, hardware and related	34,664		28,435		36,706		34,664

Support and maintenance	38,007		43,713		41,116		38,007
Revenue cycle management and related services	21,053		20,243		21,403		21,053
Electronic data interchange and data services	22,124		20,189		23,312		22,124
Professional services	6,357		9,584		8,385		6,357
Total revenues	$	122,205	$	122,164	$	130,922	$	122,205

We generate revenue from sales of licensing rights and subscriptions to our software products, hardware and third party software products, support and maintenance services, revenue cycle management and related services ("RCM"), electronic data interchange and data services (“EDI”), and professional services, such as implementation, training, and consulting performed for clients who use our products.

Consolidated revenue for the three months ended June 30, ~~2016 remained consistent at $122.2~~2017 increased $8.7 million compared to the prior year ~~period. Total~~due to increases across each of our revenue streams, except software ~~hardware~~license and ~~related increased $6.2 million, driven by an increase of $7.6 million in software~~hardware. Software related subscription services increased $4.0 million, which was driven by higher subscription sales associated with the MediTouch® cloud-based system acquired from HealthFusion and growth in subscriptions related to our interoperability, patient portal, and QSIDental Web product offerings as we continue to expand our client base. The $3.1 million increase in support and maintenance is primarily due to lower sales credits in the current year and annual increases to support and maintenance fees that are generally tied to changes in the Consumer Price Index (CPI). The $2.0 million increase in professional services is mostly associated with the acquisition of Entrada in April 2017, offset by ~~a $1.4~~lower sales of professional services due to lower client demand for our core software products and related implementation, training, and consulting services. EDI revenue increased $1.2 million, which was primarily related to EDI services sold with our MediTouch® cloud-based solutions. The $2.0 million decline in software license and hardware ~~revenue. The growth in software related subscription services is primarily attributed to sales of~~reflects the MediTouch® cloud-based system acquired from HealthFusion in January 2016, and the decline in software license and hardware revenue reflects a shift in market dynamics toward cloud-based solutions and away from perpetual license arrangements.

EDI and RCM revenue grew $1.9 million and $0.8 million, respectively, compared to the prior year period due to addition of new clients, further penetration of our existing client base, and additional cross-sell of newer products. Support and maintenance decreased $5.7 million primarily due to the disposition of Hospital Solutions Division in October 2015, an increased level of sales credits in the current period, and client attrition. Professional services revenue decreased $3.2 million as a result of lower client demandincreasingly saturated end-market for ~~implementation, training, and consulting services related to the recent decline in new system sales and market saturation of our core software products.~~electronic health records software.

Recurring service revenue, consisting of software related subscription services, support and maintenance, RCM, and EDI, represented ~~82.7%~~83.8% and ~~78.9%~~82.7% of total revenue for the three months ended June 30, ~~2016~~2017 and ~~2015,~~2016, respectively.

~~We expect~~Our goals include further enhancement of our existing products, including expansion of our software and service offerings that support pay-for-performance initiatives around accountable care organizations, bringing greater ease of use and intuitiveness to ~~benefit from the growth~~our software products, enhancing our managed cloud and hosting services to lower our clients' total cost of a replacement market driven by an expected consolidation of electronic health records vendors. We also anticipate the creation of new opportunities in connection with the evolution of healthcare from a fee-for-services reimbursement model to a pay-for-performance model around the management of patient populations. Our acquisitions of Gennius and Mirth provided us with new products and services around population health, collaborative care management,ownership, expanding our interoperability and enterprise analytics capabilities, and further development and enhancements of our portfolio of specialty focused templates within our electronic health records software.

We intend to remain at the forefront of upcoming new regulatory requirements, including meaningful use requirements for stimulus payments and recent healthcare reform that is driving the transition towards pay-for-performance, value-based reimbursement models. We believe that the expanded requirements for continued eligibility for incentive payments under meaningful use rules will result in an expanded replacement market for electronic health records software. We also intend to continue selling additional software and services to existing clients, expanding penetration of connectivity and other services to new and existing clients, and capitalizing on growth and cross selling opportunities. Our acquisitions of Entrada and HealthFusion has allowed us to expand our client base and cloud-based solution capabilities in the ambulatory market and meet the needs of practices of increasing size and complexity. Our acquisitions of Mirth and Gennius improve our competitiveness in the markets and provides us with new client opportunities and expanded markets that support our strategy to focus on accountable care organizations around interoperability, patient engagements, population health and collaborative care management, and enterprise analytics. When combined, we can offer our clients a full suite of cloud-based solutions that better enable our clients to focus on care delivery. We believe we are well-positioned within the evolving healthcare market to deliver products and services that address ~~these market dynamics.~~ the growing importance of quality collaborative care and shift from fee-for-service to value-based, pay-for-performance care. We also believe that a significant opportunity exists to continue cross selling RCM services to our existing clients as the portion of existing clients who are using RCM services is approximately 10%. We are actively pursuing efforts to achieve faster growth from expanded efforts to leverage our existing sales force towards selling RCM services. We also believe that ongoing increases in the complexity of medical billing and collections processes, including the migration to value-based reimbursement models, will create additional opportunities.

While it remains difficult to assess the relative impact or the timing of positive and negative trends affecting the aforementioned market opportunities, we believe we are well positioned to remain a leader in serving the evolving market needs for healthcare information technology. We believe that our operating results are attributed to a strong brand name and reputation within the marketplace for healthcare information technology software and services and investments in sales and marketing activities, including new marketing campaigns, Internet advertising investments, tradeshow attendance and other expanded advertising and marketing expenditures.

Gross Profit

The following table presents our consolidated cost of revenue and gross profit for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016 (in thousands):


	Three Months Ended June 30,						Three Months Ended June 30,
	2016			2015			2017			2016
Total cost of revenue	$	56,815		$	55,977		$	59,169		$	56,815
Gross profit	65,390			66,187			71,753			65,390
Gross margin %	53.5		%	54.2		%	54.8		%	53.5		%

Cost of revenue consists primarily of compensation expense, including share-based compensation, for personnel that deliver our products and services. Cost of revenue also includes amortization of capitalized software costs and acquired technology, third

party consultant and outsourcing costs, costs associated with our EDI business partners and clearinghouses, hosting service costs, third party software costs and royalties, and other costs directly associated with delivering our products and services. Refer to Note 5, "Intangible Assets" and Note 6, "Capitalized Software Costs" of our notes to consolidated financial statements included elsewhere in this Report for additional information on current period amortization of capitalized software costs and acquired technology and an estimate of future expected ~~amortization of capitalized software costs.~~amortization.

Share-based compensation expense included in cost of revenue was $0.1 million ~~and $0.1 million~~ for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016, and is included in the amounts in the table above.

Gross profit ~~decreased $0.8~~for the three months ended June 30, 2017 increased $6.4 million compared to the prior year period due primarily to $8.7 million higher revenues as discussed above, offset by a $2.4 million increase in cost of revenue. The increase in cost of revenue is due to higher costs associated with the acquisition of Entrada in April 2017, higher amortization of the software technology intangible asset acquired from ~~HealthFusion, partially offset by lower payroll~~Entrada, and higher personnel costs associated with delivering support and maintenance and ~~professional services.~~RCM services, partially offset by lower amortization of previously capitalized software development cost. The gross margin percentage ~~remained consistent~~increased to 54.8% for the three months ended June 30, 2017 compared to 53.5% in the prior year ~~period.~~period due mostly to growth in our higher-margin software related subscription services.

Selling, General and Administrative Expense

The following table presents our consolidated selling, general and administrative expense for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016 (in thousands):


	Three Months Ended June 30,						Three Months Ended June 30,
	2016			2015			2017			2016
Selling, general and administrative	$	40,581		$	39,171		$	42,977		$	40,581
Selling, general and administrative, as a percentage of revenue	33.2		%	32.1		%	32.8		%	33.2		%

Selling, general and administrative expense consist of compensation expense, including share-based compensation, for management and administrative personnel, selling and marketing expense, facilities costs, depreciation, professional service fees, including legal, consulting, and accounting services, acquisition and transaction-related costs, and other general corporate and administrative expenses.

Share-based compensation expense included in selling, general and administrative expenses was ~~$1.0~~$1.5 million and ~~$0.5~~$1.0 million for the three months ended June 30, ~~2016~~2017 and ~~2015,~~2016, respectively, and is included in the amounts in the table above.

Selling, general and administrative expenses increased $2.4 million for the three months ended June 30, ~~2016 increased $1.4 million~~2017 compared to the prior year ~~period primarily~~ due to ~~the~~higher incremental costs associated with Entrada acquired in April 2017, an increase in bad debt expense associated with ~~the acquisition of HealthFusion in January 2016, a $1.8 million increase in amortization of intangibles acquired from HealthFusion,~~our continued efforts to resolve aged customer receivable balances, and ~~$1.9 million increase in acquisition costs primarily related to the fair value adjustments of contingent consideration, partially offset by lower payroll~~higher consulting costs associated with ~~the corporate restructuring plan (refer to Note 15, "Restructuring Plan" of~~ our ~~notes to consolidated financial statements included elsewhere in this Report for additional information)~~assessment and ~~the disposition~~implementation of the ~~Hospital Solutions Division in October 2015.~~new revenue standard (ASC 606, Revenue From Contracts With Customers), including implementation of a new accounting system module.

Research and Development Costs, net

The following table presents our consolidated net research and development costs, capitalized software costs, and gross expenditures prior to capitalization, for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016 (in thousands):


	Three Months Ended June 30,						Three Months Ended June 30,
	2016			2015			2017			2016
Gross expenditures	$	21,172		$	20,720		$	25,237		$	21,172
Capitalized software costs	(2,948		)	(3,635		)	(5,248		)	(2,948		)
Research and development costs, net	$	18,224		$	17,085		$	19,989		$	18,224

Research and development costs, net, as a percentage of revenue	14.9		%	14.0		%
Research and development costs, as a percentage of revenue							15.3		%	14.9		%
Capitalized software costs as a percentage of gross expenditures	13.9		%	17.5		%	20.8		%	13.9		%

Gross research and development expenditures, including costs expensed and costs capitalized, consist of compensation expense, including share-based compensation for research and development personnel, certain third-party consultant fees, software maintenance costs, and other costs related to new product development and enhancement to our existing products. We intend to continue to invest heavily in research and development expenses as we continue to bring additional functionality and features to the medical community and develop a new integrated inpatient and outpatient, web-based software platform.

The capitalization of software development costs results in a reduction to our reported net research and development costs. Our software capitalization rate, or capitalized software costs as a percentage of gross expenditures, has varied historically and may continue to vary based on the nature and status of specific projects and initiatives in progress. Although changes in software capitalization rates have no impact on our overall cash flows, it results in fluctuations in the amount of software development costs

being expensed up front and the amount of net research and development costs reported in our consolidated statement of net income and comprehensive income.

Share-based compensation expense included in ~~net~~ research and development costs was $0.4 million and $0.1 million for ~~both~~ the three months ended June 30, 2017 and 2016, ~~and~~ ~~2015~~respectively, and is included in the amounts in the table above.

Net research and development costs for the three months ended June 30, ~~2016~~2017 increased ~~$1.1~~$1.8 million compared to the prior year, ~~period~~which as due to a ~~result of a $0.5~~$4.1 million increase in our gross expenditures, ~~and a $0.7~~offset by $2.3 million ~~decline in capitalized~~higher capitalization of software costs. The increase in both gross expenditures isand capitalization of software costs are related to the ~~acquisition of HealthFusion and increased investment in the~~ development of ~~new~~the next major versions of our core software products ~~partially offset by lower gross expenditures related~~and enhancements to the discontinuation of the NextGen Now development project during the fourth quarter of fiscal 2016 and lower personnel costs associated with the restructuring plan. The reduction in capitalized software costs is due to a decline in the rate of theour existing products. Our software capitalization rate fluctuates due to ~~13.9% compared to 17.5%~~differences in the ~~prior year period, which reflects a trend towards a more agile development approach that inherently shortens the time frame during which development costs may be capitalized~~nature and ~~the various stages~~status of ~~software development~~our projects and initiatives during a given ~~period.~~year, which affects the amount of development costs that may be capitalized.

Amortization of Acquired Intangible Assets

The following table presents our amortization of acquired intangible assets for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016 (in thousands):

Three Months Ended June 30,
2016 2015
Amortization of acquired intangible assets $ 2,704
$ 897



	Three Months Ended June 30,
	2017		2016
Amortization of acquired intangible assets	$	2,047	$	2,704

Amortization of acquired intangible assets included in operating expense consist of the amortization related to our customer relationships, trade name, and contracts intangible assets acquired as part of our business combinations. Refer to Note 5, "Intangible Assets" of our notes to consolidated financial statements included elsewhere in this Report for an estimate of future expected amortization.

Amortization of acquired intangible assets for the three months ended June 30, ~~2016 increased $1.7 million~~2017 declined compared to the ~~prior year~~three months ended June 30, 2016 is due to ~~additional amortization of the customer relationships and trade name~~certain acquired intangible assets ~~related to~~being fully amortized during the ~~acquisition of HealthFusion. Refer to Note 5, "Business Combinations" of our notes to consolidated financial statements included elsewhere in this Report for additional information.~~year, partially offset by the incremental amortization associate with intangible assets acquired from Entrada.

Restructuring Costs

During the three months ended June 30, 2016, we recorded $3.8 million of restructuring costs within operating expenses in our consolidated statements of comprehensive income. The restructuring costs resulted from a restructuring plan that we announced in April 2016, ~~whereby we reduced our domestic headcount by approximately 150 employees, or approximately six percent of our U.S.-based workforce,~~ and such costs consist primarily of payroll-related costs, such as severance, outplacement costs, and continuing

healthcare coverage, associated with the involuntary separation of employees pursuant to a one-time benefit arrangement. AsThe restructuring plan was substantially complete by the end of fiscal 2017, and thus we did not incur additional restructuring costs during the three months ended June 30, ~~2016, we had a remaining liability of $1.3 million related to our restructuring costs, which we expect to settle in the second quarter of fiscal~~ 2017.

The restructuring is part of a three-phase plan initiated in fiscal year 2016 that was intended to better position our organization for future success. In the first phase, we restructured the organization to more effectively support the execution of our strategy. We believe that the restructuring will reduce our costs and improve our financial performance. As we begin phase two of our reorganization, we expect to continue building and enhancing the capabilities that will drive future revenue growth. The third phase of the plan will consist of developing the services and solutions to accelerate revenue growth.

~~Refer to Note 15, "Restructuring Plan" of our notes to consolidated financial statements included elsewhere in this Report for additional information.~~

Interest and Other Income and Expense

The following table presents our interest expense for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016 (in thousands):


	Three Months Ended June 30,						Three Months Ended June 30,
	2016			2015			2017			2016
Interest income	$	8		$	302		$	9		$	8
Interest expense	(1,013		)	—			(677		)	(1,013		)
Other expense, net	(87		)	(50		)	(22		)	(87		)

~~Interest income relates primarily to our marketable securities.~~ Interest expense relates to our revolving credit agreement that was entered into in January 2016 and the related amortization of deferred debt issuance costs. Refer to Note 7, “Line of Credit” of our notes to consolidated financial statements included elsewhere in this Report for additional information. ~~Other expense and income relates primarily to net realized gains and losses on our marketable securities.~~

Interest expense for the ~~year ended~~ three months ended June 30, ~~2016 increased $1.0~~2017 decreased $0.3 million compared to the prior year. The ~~increase~~decrease in interest expense is primarily ~~related to the interest expense~~ associated with lower average outstanding balances under our revolving credit agreement ~~and~~in the ~~amortization of deferred debt issuance costs.~~current year compared to prior year. As of June 30, ~~2016,~~2017, we had ~~$88.0~~$45.0 million in outstanding loans under the revolving credit agreement.

All other fluctuations in interest and other income and expense are not deemed significant.

Provision for ~~(benefit~~(Benefit of) Income Taxes

The following table presents our provision for (benefit of) income taxes for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016 (in thousands):


	Three Months Ended June 30,						Three Months Ended June 30,
	2016			2015			2017			2016
Provision for (benefit of) income taxes	$	(317	)	$	2,924		$	2,154		$	(317	)
Effective tax rate	32.9		%	31.5		%	35.6		%	32.9		%

The effective rate for the ~~three~~Three months ended June 30, ~~2016~~2017 increased compared to the prior year period primarily due to ~~lower qualifying production activity deductions,~~the impact of share-based compensation shortfall expense in current period, offset by a favorable ~~impact~~benefit in current period of ~~the research~~state taxes and ~~development credit.~~exclusion of certain non-deductible acquisition-related costs.

Net Income (Loss)

The following table presents our net income (loss) (in thousands) and net income (loss) per share and for the three months ended June 30, ~~2016~~2017 and ~~2015~~ ~~(in thousands):~~2016:


	Three Months Ended June 30,					Three Months Ended June 30,
	2016			2015		2017		2016
Net income (loss)	$	(647	)	$	6,362	$	3,896	$	(647	)
Net income (loss) per share:
Basic	$	(0.01	)	$	0.11	$	0.06	$	(0.01	)
Diluted	$	(0.01	)	$	0.10	$	0.06	$	(0.01	)

As a result of the foregoing changes in revenue and expense, net income for the three months ended June 30, ~~2016 decreased $7.0~~2017 increased $4.5 million compared to the prior year period. Specifically, the decrease in net income is due to the $3.8 million of restructuring costs, combined with a $1.9 million increase in acquisition costs primarily related to the fair value adjustments of contingent consideration, $1.7 million higher amortization of intangible assets associated with the acquisition of HealthFusion, $1.1 million higher net research and development costs, and $1.0 million increase in interest expense in connection with the revolving credit agreement, partially offset by lower payroll costs associated with the corporate restructuring plan and the disposition of the Hospital Solutions Division in October 2015.

~~Operating Segment Information~~

Our business divisions consist of the NextGen Division, the RCM Services Division, and the QSI Dental Division. Our divisions share the resources of our “corporate office,” which includes a variety of accounting, finance and other administrative functions.

~~The following table presents an overview of our operating results by segment for the three months ended June 30, 2016 and~~ ~~2015~~ ~~(in thousands):~~

Three Months Ended June 30,
2016 2015
Revenue:
NextGen Division $ 95,556
$ 91,615
RCM Services Division 22,365
22,462
QSI Dental Division 4,284
4,418
Hospital Solutions Division ⁽¹⁾
—
3,669
Consolidated revenue $ 122,205
$ 122,164

Operating income:
NextGen Division $ 45,649
$ 44,858
RCM Services Division 4,458
4,417
QSI Dental Division 1,877
950
Hospital Solutions Division ⁽¹⁾
—
955
Corporate and unallocated (51,856 ) (42,146 )
Consolidated operating income $ 128
$ 9,034

⁽¹⁾~~The former Hospital Solutions Division was divested in October 2015.~~

~~NextGen Division~~

NextGen Division revenue for the three months ended June 30, 2016 increased $3.9 million and divisional operating income increased $0.8 million compared to the prior year period. The increase in revenue was driven by a $8.7 million increase in our software related subscription services attributed mostly to the acquisition of HealthFusion in January 2016 and a $1.7 million increase in EDI revenue from the addition of new clients and further penetration of our existing client base. Such increases in revenue were partially offset by a $3.0 million decrease in support and maintenance, a $2.4 million decrease in professional services and a $1.1 million decrease in software license and hardware revenue, resulting from of a shift in market dynamics toward cloud-based solutions and away from perpetual license arrangements, resulting in lower client demand for our core software products and related support and maintenance, implementation, training, and consulting services.

The increase in divisional operating income is primarily the result of higher gross profit from the aforementioned increases in revenue, partially offset by an increase in overall operating expenses attributed to the acquisition of HealthFusion.

Our goals for the NextGen Division include further enhancement of our existing products, including expansion of our software and service offerings that support pay-for-performance initiatives around accountable care organizations, bringing greater ease of use and intuitiveness to our software products, enhancing our managed cloud and hosting services to lower our clients' total cost of ownership, expanding our interoperability and enterprise analytics capabilities, and further development and enhancements of our portfolio of specialty focused templates within our electronic health records software. We intend to remain at the forefront of upcoming new regulatory requirements, including meaningful use requirements for stimulus payments and recent healthcare reform that is driving the transition towards pay-for-performance, value-based reimbursement models. We believe that the expanded requirements for continued eligibility for incentive payments under meaningful use rules will result in an expanded replacement market for electronic health records software. We also intend to continue selling additional software and services to existing clients, expanding penetration of connectivity and other services to new and existing clients, and capitalizing on growth and cross selling opportunities within the RCM Services Division. Our acquisition of HealthFusion will allow us expand our client base and cloud-based solution capabilities in the ambulatory market and meet the needs of practices of increasing size and complexity. Our acquisitions of Mirth and Gennius improve our competitiveness in the markets and provide new clients and expanded markets for the NextGen Division and also support our strategy to focus on accountable care organizations around interoperability, patient engagements, population health and collaborative care management, and enterprise analytics. We believe we are well-positioned within the evolving healthcare market to deliver products and services that address the growing importance of quality collaborative care and shift from fee-for-service to value-based, pay-for-performance care.

We believe that the NextGen Division’s results are attributed to a strong brand name and reputation within the marketplace for healthcare information technology software and services and investments in sales and marketing activities, including new marketing campaigns, Internet advertising investments, tradeshow attendance and other expanded advertising and marketing expenditures.

~~RCM Services Division~~

RCM Services Division revenue and divisional operating income remained consistent for the three months ended June 30, 2016 compared to the prior year period. We believe that a significant opportunity exists to continue cross selling RCM services to existing clients. The portion of existing NextGen clients who are using the RCM Services Division's services is less than 10%. We are actively pursuing efforts to achieve faster growth from expanded efforts to leverage the existing NextGen Division's sales force towards selling RCM services. We also believe that ongoing increases in the complexity of medical billing and collections processes, including the migration to value-based reimbursement models, will create additional opportunities for our RCM Services Division.

~~QSI Dental Division~~

QSI Dental Division revenue for the three months ended June 30, 2016 decreased $0.1 million and divisional operating income increased $0.9 million compared to the prior year period. The decrease in revenue was driven by lower software, hardware, and related revenues, partially offset by an increase in QSI Dental EDI revenue. The increase in divisional operating income was the result of lower cost of revenue associated with the delivery of our products and services, including lower payroll costs related to decreases in divisional headcount and lower third party consultant and outsourcing costs.

We believe that the QSI Dental Division is well-positioned to sell to the FQHCs market and intends to continue leveraging the NextGen Division's sales force to sell its dental electronic medical records software to practices that provide both medical and dental services, such as FQHCs, which are receiving grants as part of the ARRA. Our goal for the QSI Dental Division is to continue to invest in the cloud-based QSIDental Web platform while aggressively marketing QSIDental Web to both new and existing clients.

~~Corporate and unallocated~~

~~The major components of the corporate and unallocated amounts are summarized in the table below (in thousands):~~

Three Months Ended June 30,
2016 2015
Research and development costs, net $ 18,224
$ 17,085
Amortization of capitalized software costs 2,371
2,439
Marketing expense 2,943
3,816
Restructuring costs 3,753
—
Other corporate and overhead costs ⁽¹⁾
24,565
18,806
Total corporate and unallocated 51,856
42,146

The amounts classified as corporate and unallocated consist primarily of corporate general and administrative costs, acquisition and transaction-related costs, amortization of acquired intangible assets, amortization of capitalized software costs, and costs of other centrally managed overhead and shared-services functions, including accounting and finance, human resources, information services, marketing, legal, and research and development, that are not controlled by segment level leadership. Although the segments may derive direct benefits as a result of such costs, our chief operating decision maker (consisting of our Chief Executive Officer) evaluates performance based upon stand-alone segment operating income, which excludes these corporate and unallocated amounts.

Corporate and unallocated expense for the three months ended June 30, 2016 increased $9.7 million compared to the prior year period. The net increase in corporate and unallocated expense is primarily the result of a $5.8 million increase in other corporate and overhead costs, which was related to higher amortization of acquired intangible assets and other general and administrative costs associated with the acquisition of HealthFusion, higher acquisition costs (including fair value adjustments to contingent consideration liabilities), and higher professional services costs. Total corporate and unallocated expense also increased due to $3.7 million of restructuring costs recorded during the period and a $1.1 million increase in net research and development costs. Refer to the corresponding sections above titled "Restructuring Costs" and "Research and Development, net" for additional information regarding restructuring costs and net research and development costs.

Liquidity and Capital Resources

The following table presents selected financial statistics and information for the three months ended June 30, ~~2016~~2017 and ~~2015~~2016 (in thousands):


	Three Months Ended June 30,					Three Months Ended June 30,
	2016			2015		2017		2016
Cash and cash equivalents and marketable securities	$	26,349		$	116,797
Cash and cash equivalents						$	23,337	$	26,349
Unused portion of revolving credit agreement ⁽¹⁾	162,000			—		205,000		162,000
Total liquidity	$	188,349		$	116,797	$	228,337	$	188,349

Net income (loss)	$	(647	)	$	6,362	$	3,896	$	(647	)
Net cash provided by operating activities	$	12,933		$	3,707	$	12,794	$	12,933

_________________________

⁽¹⁾ As of June 30, ~~2016,~~2017, we had ~~our~~ outstanding loans of ~~$88.0~~$45.0 million under our $250.0 million revolving credit agreement.

~~Cash Flows~~Our principal sources of liquidity are our cash generated from ~~Operating Activities~~

~~The following table summarizes our consolidated statements of cash flows for the three months ended June 30, 2016 and 2015 (in thousands):~~

Three Months Ended June 30,
2016 2015
Net income (loss) $ (647 ) $ 6,362
Non-cash expenses 17,039
8,318
Cash from net income (loss), as adjusted 16,392
14,680

Change in other assets and liabilities (3,459 ) (10,973 )
Net cash provided by operating activities $ 12,933
$ 3,707

For the three months ended June 30, 2016, cash provided by operating activities increased $9.2 million compared to the prior year period, which improvement is primarily due to changes in assets and, to a lesser extent, an increase in net income as adjusted to exclude non-cash expenses. The reduction in cash flows due to changes in assets and liabilities isoperations, driven mostly attributed to decreases in income taxes payable and an increase in accounts receivable, partially offset a decrease in cash paid for accounts payables. The increase in non-cash expenses was primarily the result of higher amortization of intangibles associated with the acquisition of HealthFusion, changes in the fair value of contingent consideration liabilities, and restructuring costs, net of amounts paid. Refer to the "Net Income" section above for additional details regarding the fluctuations in net income.

~~Cash provided by operating activities has historically been, and is expected to continue to be, our primary source of cash, driven~~ by our net income and working capital ~~management.~~

~~Cash Flows from Investing Activities~~

~~Net~~management, our cash ~~provided by investing activities for the three months ended June 30, 2016 was $2.9 million compared with $7.4 million~~and cash used in investing activities in the prior year period. The $10.2 million increase in net cash from investing activities is primarily due to a $9.7 million net increase in cash from the sales of marketable securitiesequivalents, and ~~a $0.7 million decrease in additions to capitalized software, partially offset by a $0.1 million increase in additions to equipment and improvements.~~

~~Cash Flows from Financing Activities~~

Net cash used in financing activities for the three months ended June 30, 2016 was $16.6 million compared with $10.5 million in the prior year period. The increase in cash used in financing activities relates to $17.0 million of principal repayments on our revolving ~~line of~~ credit ~~partially offset by $10.7 million in dividends paid to shareholders during the prior year period.~~

agreement.

Cash and Cash Equivalents

As of June 30, ~~2016,~~2017, our cash and cash equivalents balance of ~~$26.3~~$23.3 million reflects a ~~$10.1~~$14.3 million decrease compared to ~~$36.5~~$37.7 million ~~of cash, cash equivalents and marketable securities~~ as of March 31, ~~2016.~~2017. This decrease primarily reflects ~~$17.0~~$33.9 million paid for the acquisition of Entrada in April 2017 and payment of $18.8 million in May 2017 to settle the contingent consideration liability related to the acquisition of HealthFusion, partially offset by $30.0 million of ~~principal repayments on~~additional borrowings under our revolving ~~line of~~ credit ~~offset by an increase in cash provided by operating activities, as noted above.~~

In January 2016, we entered into a $250.0 million revolving credit agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and certain other lenders.agreement. Our outstanding loans under ~~the Credit Agreement~~our revolving credit agreement was ~~$88.0~~$45.0 million as of June 30, ~~2016.~~2017.

We may continue to use a portion of our funds as well as available financing from ~~the Credit Agreement~~our revolving credit agreement for future acquisitions or other similar business activities, although the specific timing and amount of funds to be used is not currently determinable. ~~Our principal sources of liquidity are our cash and cash equivalents, the Credit Agreement, as well as our cash generated from operations.~~ We intend to expend some of our available funds for the development of products complementary to our existing product line as well as new versions of certain of our products. These developments are intended to take advantage of more powerful technologies and to increase the integration of our products.

Our investment policy is determined by our Board of Directors. ~~We currently maintain our~~Excess cash, if any, may be invested in very liquid short term assets including tax exempt and taxable money market funds, certificates of deposit and short term municipal bonds with average maturities of 365 days or less at the time of purchase. Our Board of Directors continues to review alternate uses for our cash including an expansion of our investment policy and other items. Any or all of these programs could significantly impact our investment income in future periods.

We believe that our cash and cash equivalents ~~and marketable securities~~ on hand at June 30, ~~2016,~~2017, together with our cash flows from operations and liquidity provided by ~~the Credit Agreement,~~our revolving credit agreement, will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months.

Cash Flows from Operating Activities

The following table summarizes our consolidated statements of cash flows for the three months ended June 30, 2017 and 2016 (in thousands):



	Three Months Ended June 30,
	2017			2016
Net income (loss)	$	3,896		$	(647	)
Non-cash expenses	14,350			17,039
Cash from net income, as adjusted	$	18,246		$	16,392

Change in other assets and liabilities	(5,452		)	(3,459		)
Net cash provided by operating activities	$	12,794		$	12,933

For the three months ended June 30, 2017, cash provided by operating activities decreased $0.1 million compared to the prior year period primarily due to higher net income as adjusted to exclude non-cash expenses, which was partially offset by higher cash used related to changes in other assets and liabilities.

Cash Flows from Investing Activities

Net cash used in investing activities for the three months ended June 30, 2017 was $41.6 million compared with $2.9 million of cash provided by investing activities in the prior year period. The increase in net cash used in investing activities is primarily due to $33.9 million paid for the acquisition of Entrada, $9.3 million lower proceeds from sales of marketable securities, and $2.3 million increase in additions to capitalized software costs associated with the development of new products and enhancement of existing products.

Cash Flows from Financing Activities

Net cash provided by financing activities for the three months ended June 30, 2017 was $14.4 million compared with $16.6 million cash used by financing activities in the prior year period. The increase in cash provided in financing activities relates to $30.0 million of additional borrowings under our revolving credit agreement in current year period compared to $17.0 million in principal repayments during the prior year period.

Contractual Obligations

The following table summarizes our significant contractual obligations at June 30, ~~2016~~2017 and the effect that such obligations are expected to have on our liquidity and cash in future periods (in thousands):


			For the year ended March 31,														For the year ended March 31,
Contractual Obligations	Total		2017 (remaining nine months)		2018		2019		2020		2021		2022 and beyond		Total		2018 (remaining nine months)		2019		2020		2021		2022		2023 and beyond
Operating lease obligations ⁽¹⁾	$	71,167	$	7,527	$	10,339	$	9,364	$	8,444	$	8,421	$	27,072	$	60,196	$	6,456	$	8,767	$	8,445	$	8,416	$	8,125	$	19,987
Line of credit obligations	$	88,000	—		$	—	$	—	—		88,000		—
Contingent consideration and other acquisition related liabilities (excluding share-based payments)	$	17,600	17,600		$	—	$	—	—		—		—
Remaining lease obligations for vacated properties ⁽¹⁾															6,307		2,195		1,413		794		816		551		538
Line of credit obligations (Note 7)															45,000		—		—		—		45,000		—		—
Purchase commitments ⁽²⁾															$	3,488	$	938	$	1,250	$	1,300	$	—	$	—	$	—
Total	$	176,767	$	25,127	$	10,339	$	9,364	$	8,444	$	96,421	$	27,072	$	114,991	$	9,589	$	11,430	$	10,539	$	54,232	$	8,676	$	20,525

_________________________

⁽¹⁾ ~~Operating~~Remaining lease obligations for vacated properties relates to remaining lease obligations at certain locations, including Austin, Solana Beach, Costa Mesa, and a portion of Horsham, that we have vacated and are actively marketing the locations for sublease as part of our reorganization efforts. Total obligations have not been reduced by projected sublease rentals or by minimum sublease rentals of ~~$2.4~~$1.4 million due in future periods under ~~our~~ non-cancelable subleases.

⁽²⁾Purchase commitments relates to payments due under certain non-cancelable agreements to purchase goods and services.

The deferred compensation liability as of June 30, ~~2016~~2017 was ~~$6.6~~$6.4 million, which is not included in the table above as the timing of future benefit payments to employees is not determinable.

The uncertain tax position liability as of June 30, ~~2016~~2017 was ~~$4.0~~$5.1 million, which is not included in the table above as the timing of expected payments is not determinable.

New Accounting Pronouncements

Refer to Note 1, “Summary of Significant Accounting Policies” of our notes to consolidated financial statements included elsewhere in this Report for a discussion of new accounting standards.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As of June 30, ~~2016,~~2017, we were subject to minimal market risk on our cash and cash equivalents as we maintained our balances in very liquid ~~money market~~ funds ~~and short-term U.S. Treasury securities~~ with maturities of 90 days or less at the time of purchase.

As of June 30, ~~2016,~~2017, we had ~~$88.0~~$45.0 million in outstanding loans under our revolving credit agreement. The revolving loans under the agreement bear interest at our option of either, (a) a base rate based on the highest of (i) the rate of interest per annum publicly announced from time to time by JPMorgan Chase Bank, N.A., as its prime rate, (ii) the greater of (A) the federal funds effective rate and (B) the overnight bank funding rate (as determined by the Federal Reserve Bank of New York) plus 0.50% and (iii) the one-month British Bankers Association London Interbank Offered Rate ("LIBOR") plus 1.00%) plus an applicable margin based on our leverage ratio from time to time, ranging from 0.50% to 1.50%, or (b) a LIBOR-based rate (subject to a floor of 0.00%) plus an applicable margin based on our leverage ratio from time to time, ranging from 1.50% to 2.50%. Accordingly, we are exposed to interest rate risk, primarily changes in LIBOR, due to our loans under the revolving credit agreement. A one hundred basis point (1.00%) change in the interest rate on our outstanding loans as of June 30, ~~2016~~2017 would result in a corresponding change in our annual interest expense of approximately ~~$0.9~~$0.5 million. Refer to Note 7, “Line of Credit” of our notes to consolidated financial statements included elsewhere in this Report for additional information.

As of June 30, ~~2016,~~2017, we had international operations that exposed us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. However, the impact of foreign currency fluctuations has not been material to our financial position or operating results.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively) have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Security Exchange Act of 1934, as amended, the "Exchange Act") as of June 30, ~~2016,~~2017, the end of the period covered by this Quarterly Report on Form 10-Q (the “Evaluation Date”). They have concluded that, as of the Evaluation Date, these disclosure controls and procedures were effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities and would be disclosed on a timely basis. The Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are designed, and are effective, to give reasonable assurance that the information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the rules and forms of the Securities and Exchange Commission. They have also concluded that ~~the~~ our disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that are filed or submitted under the Exchange Act are accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the quarter ended June 30, ~~2016,~~2017, there were no changes in our “internal control over financial reporting” (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

Hussein Litigation

On October 7, 2013, a complaint was filed against our Company and certain of our officers and directors in the Superior Court of the State of California for the County of Orange, captioned Ahmed D. Hussein v. Sheldon Razin, Steven Plochocki, Quality Systems, Inc. and Does 1-10, inclusive, No. 30-2013-00679600-CU-NP-CJC, by Ahmed Hussein, a former director and significant shareholder of our Company. We filed a demurrer to the complaint, which the ~~court~~Court granted on April 10, 2014. An amended complaint was filed on April 25, 2014. The amended complaint generally alleges fraud and deceit, constructive fraud, negligent misrepresentation and breach of fiduciary duty in connection with statements made to our shareholders regarding our financial condition and projected future performance. The amended complaint seeks actual damages, exemplary and punitive damages and costs. We filed a demurrer to the amended complaint. On July 29, 2014, the ~~court~~Court sustained the demurrer with respect to the breach of fiduciary duty claim, and overruled the demurrer with respect to the fraud and deceit claims. On August 28, 2014, we filed an answer and also filed a cross-complaint against the plaintiff, alleging that the plaintiff breached fiduciary duties owed to the Company, Mr. Razin and Mr. Plochocki. Mr. Razin and Mr. Plochocki have dismissed their claims against Hussein, leaving QSI as the sole plaintiff in the cross-complaint. On June 26, 2015, we filed a motion for summary judgment, which the ~~court~~Court granted on September 16, 2015, dismissing all claims against us. On September 23, 2015, the plaintiff filed an application for reconsideration of the ~~Court’s~~Court's summary judgment order, which the ~~court~~Court denied. On October 28, 2015, the plaintiff filed a motion for summary judgment, seeking to dismiss our cross-complaint, which the ~~court~~Court denied on March 3, 2016. On May 9, 2016, the plaintiff filed a motion for summary adjudication, seeking to again dismiss our cross-complaint, which the Court denied on August 5, 2016. On August 5, 2016, the plaintiff filed a motion for judgment on the pleadings, seeking to again dismiss our cross-complaint, which the Court denied on September 2, 2016. Trial on our cross-complaint began June 12, 2017. On July 26, 2017, the Court issued a statement of decision granting Hussein’s motion for judgment on our cross-complaint. ~~The hearing for~~We believe the ~~motion is set for August 4, 2016.~~Court’s decision on our cross-complaint was erroneous and we are evaluating a potential appeal. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Federal Securities Class Action

On November 19, 2013, a putative class action complaint was filed on behalf of the shareholders of our Company other than the defendants against us and certain of our officers and directors in the United States District Court for the Central District of California by one of our shareholders. After the ~~court~~Court appointed lead plaintiffs and lead counsel for this action, and recaptioned the action In re Quality Systems, Inc. Securities Litigation, No. 8L13-cv-01818-CJC(JPRx), lead plaintiffs filed an amended complaint on April 7, 2014. The amended complaint, which is substantially similar to the litigation described above under the caption “Hussein Litigation,” generally alleges that statements made to our shareholders regarding our financial condition and projected future performance were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the individual defendants are liable for such statements because they are controlling persons under Section 20(a) of the Exchange Act. The complaint seeks compensatory damages, court costs and attorneys' fees. We filed a motion to dismiss the amended complaint on June 20, 2014, which the ~~court~~Court granted on October 20, 2014, dismissing the complaint with prejudice. Plaintiffs filed a motion for reconsideration of the Court's order, which the ~~court~~Court denied on January 5, 2015. On January 30, 2015, Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit, captioned In re Quality Systems, Inc. Securities Litigation, No. 15-55173. ~~Plaintiffs filed their opening brief and we answered.~~ Oral argument ~~is not yet scheduled.~~was held on December 5, 2016. On July 28, 2017, the Ninth Circuit issued a decision reversing and remanding the District Court's order on our motion to dismiss. We believe that the ~~plaintiffs’~~plaintiffs' claims are without merit and continue to defend against them ~~vigorously.~~vigorously, including by evaluating potential challenges to the Ninth Circuit decision. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

Shareholder Derivative Litigation

On January 24, 2014, a complaint was filed against our Company and certain of our officers and current and former directors in the United States District Court for the Central District of California, captioned Timothy J. Foss, derivatively on behalf of himself and all others similarly situated, vs. Craig A. Barbarosh, George H. Bristol, James C. Malone, Peter M. Neupert, Morris Panner, D. Russell Pflueger, Steven T. Plochocki, Sheldon Razin, Lance E. Rosenzweig and Quality Systems, Inc., No. SACV14-00110-DOC-JPPx, by Timothy J. Foss, a shareholder of ours. The complaint arises from the same allegations described above under the captions “Hussein Litigation” and “Federal Securities Class Action” and generally alleges breach of fiduciary duties, abuse of control and gross mismanagement by our directors, in addition to unjust enrichment and insider selling by individual directors. The complaint seeks compensatory damages, restitution and disgorgement of all profits, court costs, attorneys’ fees and implementation of enhanced corporate governance procedures. The parties have agreed to stay this litigation until the United States Court of Appeals for the Ninth Circuit issues a ruling on the pending appeal described above under the caption “Federal Securities Class ~~Action”.~~Action,” and will meet and confer to discuss process going forward. We believe that the plaintiff’s claims are without merit and intend to defend against them vigorously. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this claim.

In addition to the above, we have experienced legal claims by customers regarding product and contract disputes and from time to time, claims by other third parties asserting that we have infringed their intellectual property rights. We believe that these claims, including those filed by Mr. Hussein, the Deerfield Beach Police Pension Fund and the shareholder derivative action, are without merit and intend to defend against them vigorously; however, we could incur substantial costs and diversion of management resources even if we are ultimately successful in the defense of such claims. Litigation is inherently uncertain and always difficult to predict. We refer you to the discussion of infringement and litigation risks in our “Item 1A. Risk Factors” section of our Annual Report.

Other Regulatory Matters

ITEM 1A. RISK FACTORS.

Our business is subject to many risks and uncertainties, which may materially and adversely affect our future business, prospects, financial condition and results of operations. These risk factors are disclosed in “Item 1A. Risk Factors” in our Annual Report.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not Applicable

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.



Exhibit Number	Exhibit Description	Filed Herewith

10.1	Agreement and Plan of Merger, dated April 11, 2017, by and among Quality Systems, Inc., Entrada, Inc., Engage Merger Sub, Inc. and FCA Venture Partners V, LP, as the Company Stockholders’ Representative (incorporated by reference from Exhibit 2.1 of the registrant's Current Report on Form 8-K filed April 12, 2017).
31.1	Certification of Principal Executive Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X
31.2	Certification of Principal Financial Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	X
32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	X
101.INS**	XBRL Instance
101.SCH**	XBRL Taxonomy Extension Schema
101.CAL**	XBRL Taxonomy Extension Calculation
101.DEF**	XBRL Taxonomy Extension Definition
101.LAB**	XBRL Taxonomy Extension Label
101.PRE**	XBRL Taxonomy Extension Presentation
** XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of section 11 or 12 of the Securities and Exchange Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise is not subject to liability under these section.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



			QUALITY SYSTEMS, INC.
Date:	~~July 28, 2016~~August 1, 2017	By:	/s/ John R. Frantz
			John R. Frantz
			Chief Executive Officer (Principal Executive Officer)

Date:	~~July 28, 2016~~August 1, 2017	By:	/s/ James R. Arnold
			James R. Arnold
			Chief Financial Officer (Principal Financial Officer)

~~Date:~~	~~July 28, 2016~~	~~By:~~	~~/s/ John K. Stumpf~~
			~~John K. Stumpf~~
			~~Principal Accounting Officer~~

3836



	Total Liabilities
Balance as of March 31, 2016	$	23,843
Fair value adjustments	2,574
Balance as of June 30, 2016	$	26,417



	June 30, 2016		March 31, 2016
NextGen Division	$	149,258	$	149,258
RCM Services Division	32,290		32,290
QSI Dental Division ⁽¹⁾	7,289		7,289
Total goodwill	$	188,837	$	188,837



	June 30, 2016		March 31, 2016
Computer systems and components	$	430	$	555